[Frontiers in Bioscience 15, 934-956, June 1, 2010]

Telomere attrition in lens epithelial cells - a target for N-acetylcarnosine therapy

Mark A. Babizhayev 1,2, Yegor E. Yegorov3

1Innovation Vision Products, Inc., 3511 Silverside Road, Suite 105, County of New Castle, Delaware, USA 19810, 2Moscow Helmholtz Research Institute of Eye Diseases, Str. Sadovaya-Chernogryazskaya 14/19, Moscow 103064, Russian Federation, 3Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 32 Vavilov street, Moscow, 119991, Russian Federation

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. N-acetylcarnosine and telomere shortening in human lens cells
3.1. Lens cellular structures
3.2. Peroxide threat and cellular signaling
3.3. Telomeres structures
3.4. Oxidative insult and cataract
3.5. Oxidative stress, the replicative lifespan of cells, telomere integrity and cellular senescence
3.6. Telomeres and Telomerase Activity in Lens Epithelial Cells of Normal and Cataractous Lenses
3.7. N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human eyes or visually disabling eye diseases as well as systemic health conditions
3.8. Intraocular transcorneal and systemic absorption of L-carnosine from N-acetylcarnosine ocular drug delivery system: Suitable molecular therapeutic interventions and visual sensory signaling responses
3.9. Human Lens Telomeres as a Prospective Biological Target for N-acetylcarnosine Ophthalmic Indications
3.10. The clinical effects of N-acetylcarnosine ophthalmic prodrug through protections from telomere attrition and shortening: prevention and reversal of cataracts, basic preventive health care
3.11. Prevention of complications of cataract surgery with N-acetylcarnosine ophthalmic prodrug: targeting secondary cataracts through modulation of cell senescent behavior
3.11.1. Secondary cataracts (Posterior Capsular Opacification) and their treatments
3.11.2. Treatment for Posterior Capsular Opacification
4. Summary and perspective
5. Acknowledgements
6. References

1. ABSTRACT

The lens epithelium is especially vulnerable to oxidative stress. The erosion and shortening of telomeres in human lens epithelial cells in the lack of telomerase activity has been recognized as a primary cause of premature lens senescence phenotype that trigger human cataractogenesis. Carnosine, released ophthalmically from N-acetylcarnosine prodrug lubricant eye drops , at physiological concentration might remarkably reduce the rate of telomere shortening in the lens cells subjected to oxidative stress in the lack of efficient antioxidant lens protection. The data of visual functions (visual acuity, glare sensitivity) in older adult subjects and older subjects with cataract treated with 1% N-acetylcarnosine lubricant eye drops showed significant improvement as compared, by contrast with the control group which showed generally no improvement in visual functions, with no difference from baseline in visual acuity and glare sensitivity readings. Prevention of cellular senescence with ophthalmic prodrug N-acetylcarnosine may be a novel therapeutic target in a management of cataract, basic preventive health care and in arresting of after-cataract following extracapsular cataract extraction.

2. INTRODUCTION

Originality is simply a pair of fresh eyes....Thomas W. Higginson.

Numerous reports indicate that oxidative stress is involved in cataractogenesis (1-4). Many epidemiological studies (5-10), although controversial (11), have shown that sunlight exposure, which generates reactive oxygen, could represent a major risk factor for senile cataract. Experimental data have also established that oxygen-derived free radicals induce lens opacification in animals: (12-18), and that antioxidant therapy can delay the onset of cataract in animal models (19-22). Moreover, many analytical investigations have,demonstrated that cataractous lenses contain products of oxidative processes (23-28) and are deficient in antioxidant defences (29-32).

3. N-ACETYLCARNOSINE AND TELOMERE SHORTENING IN HUMAN LENS CELLS

3.1. Lens cellular structures

The lens contains a single layer of epithelial cells that, in the equatorial region, terminally differentiate into fiber cells (33,34). There is a growth during this process, with the cell elongating toward both anterior and posterior poles. The newly formed fiber cell develops over the older fibers, increasing the volume of the lens and simultaneously displacing the older fibers in toward the center of the tissue. Thus, the inner region represents the embryonic lens, the oldest part of the tissue designated as the nucleus, and the periphery contains the youngest section, the cortex, which is the metabolically active region (Figure 1).

The nucleus, mitochondria, and other cellular organelles are degraded during the terminal differentiation process so that the fully differentiated lens fiber, which represents a large proportion of the mature lens, has lost its ability to synthesize protein and maintain metabolic processes. A consequence of this process is that the fraction of the lens that is metabolically active is constantly diminishing. It is generally believed, but not fully established, that only the epithelial cells can carry on all of the typical cellular functions.

The lens epithelium is especially vulnerable to oxidative stress (35-37). Damage to this single layer of cuboidal epithelial cells on the anterior surface of the lens can precede and contribute to lens opacification. For example, generation of reactive oxygen species (ROS) in a cultured rat lens system led to irreversible damage in the epithelial cell layer (35). Cellular and mitochondrial swelling, DNA fragmentation, and loss of cell viability were observed before cataract formation. These data emphasize the fact that the lens epithelium plays a crucial role in lens transparency.

3.2. Peroxide threat and cellular signaling

Generation of ROS can cause deleterious peroxidation of lipids, modification of proteins, and cleavage of DNA (38). However, at low concentrations, ROS, which are generated as by-products of normal mitochondrial electron transport and typically, by NAD (P)H oxidase isoforms, can serve a valuable function in cell signaling (39-42). For example, an increase in intracellular ROS via the increased expression of the GTP-binding protein racl leads to activation of the transcription factor nuclear factor-κB (41). In prokaryotes, H2O2 acts as a second messenger activating OxyR protein, a transcriptional activator of many antioxidant genes, including hydroperoxidase I and glutathione reductase (43).

3.3. Telomeres structures

Telomeres are special structures at the end of chromosomes. They shorten during each round of replication and this has been characterized as a mitotic counting mechanism. Telomeres are composed of repetitive nucleotide sequences and associated proteins that protect chromosomes from degradation and recombination. Vertebrate telomeric DNA consists of a conserved hexameric sequence (5΄-TTAGGG-3΄) arranged in tandem repeats (44-48). Telomere length is maintained by a balance between processes that lengthen and those that shorten telomeres. Evidence from various organisms suggests that several factors influence telomere length regulation, such as oxidative stress, telomere binding proteins, telomerase, and DNA replication enzymes. Telomerase is a ribonucleoprotein polymerase that specifically elongates telomeres. In most human cells telomere length is not maintained and telomerase is not active. The catalytic core of human telomerase is composed of an RNA subunit known as hTER (human telomerase RNA) and a protein subunit named as hTERT (human telomerase reverse transcriptase) (49-52). Expression of hTERT is a key step of regulation of telomerase in human cells and plays a crucial role in cellular immortalization and cancer development (53-57).

Normal human somatic cells shorten their telomeres during their lifespan leading eventually to dysfunctional telomeres, growth arrest and replicative senescence (58). Overexpression of TERT, the catalytic subunit of telomerase, counteracts telomere shortening, extends the replicative potential and prevents replicative senescence (Figure 2a-d) (59). It may also exert an antiapoptotic action at an early stage of the cell death process prior to mitochondrial dysfunction and caspase activation (60). Telomerase activity in mammals (dog, rabbit, rodents) , but not humans, is likely important in the germinative epithelium to maintain its proliferative potential and prevent cell senescence (61-63). Telomerase in lens epithelial cells in mammals may function in the quiescent, central lens to maintain telomeres damaged by oxidative stress and ultraviolet light exposure, thereby preventing accelerated loss of these elements which triggers cell senescence. It remains to be determined if the increase in telomerase activity in lens epithelial cells from cataractous lenses (61) is a primary dysregulation that may have a role in the development of the cataract, or is secondary to cataract formation (Figure 3).

In addition, there is evidence for telomere length-independent functions of telomerase, which appear to promote cell survival and stress resistance (64-68). For example, telomerase expression conferred increased resistance to specific DNA damaging agents (66,69,70) and decreased apoptosis (60,68,71,72).

3.4. Oxidative insult and cataract

Oxidative stress associated with the formation of lipid peroxides is suggested to contribute to pathological processes in ageing and systemic diseases, such as diabetes, atherosclerosis, chronic renal failure, inflammation and retinal degenerative diseases known as statistically significant risk factors for cataract (15, 34, 73-76). Glutathione-dependent enzymes in the lens have been suggested to play an important role in the detoxification of endogeneous toxicants that reach the lens from different sources (macular, retinal and other age-related ocular changes), such as hydroperoxides, 4-hydroxyalkenals, dialdehydes (including malondialdehyde), fatty acid epoxides generated during lipid peroxidation (3). The observation that lipid peroxides are elevated in the lens membranes of some patients with cataract has drawn attention to these toxic oxidant species (3,74-82). Lipid peroxides can cause cataract, producing damages to both cell membrane and cytosol regions (77-84). At the membrane, lipid hydroperoxides induce changes in permeability (85-88), refashion the micro-viscosity (order) of its lipid-protein environment (89-93), cause an uncoupling of the membrane-bound enzyme Na,K-ATPase and oxidative inhibition of Ca 2+-ATPase in several tissues including the lens (94,95). Within the cell, lipid peroxides can damage DNA (96), induce a drop in total glutathione and dramatic change in the redox ratio of glutathione, lead to the appearance of new fluorophores and large protein aggregates with low solubility (clouding matrix) in the lens matter (97-102). Some authors advanced the hypothesis that H2O2, free radical (O2�˙, OH˙) and singlet (1ΔgO2) forms of oxygen are toxic, and may be generated in excessive amounts in several experimental cataracts and in human senile cataract as a consequence of lens photooxidation (103,104), radical generation by xenobiotics (105), or impaired enzymatic and non-enzymatic defenses which exist in the eye lens (106-110). The lens is well equipped with enzymatic antioxidant protective systems (i.e., superoxide dismutase , catalase, glutathione peroxidase) and endogenous free radical scavengers (e.g. glutathione, ascorbic acid), which both lose their efficiency with age and in cataracts (105,106, 111-118). The high levels of reduced glutathione (GSH) in the normal human lens (in excess of 10 mM) (118) and ascorbate in the lens and the aqueous humour (1 mM) (112-114) have been proposed to be a natural protection against photooxidation (116,119). The paradox of lens oxidative alterations in the eye, despite the high concentrations of antioxidants can be manifested since the above-mentioned reductants may undergo pro-oxidant activation in the presence of transition metal ions or endogenous photosensitizers (120). Both copper and iron promote H2O2 and free radical production from ascorbate or the cysteine residue of glutathione and the extent of this catalysis correlates with the cell toxicity (120,121). Transition metal ions are important components of non-enzymatic tissue peroxidation and they may be present in the eye tissues and fluids in catalytically active concentrations (122,123). Besides, aqueous and plasma Cu2+ levels have been reported to increase with age, in ocular inflammation and in diabetes, the etiologies which are considered to be the risk factors of cataract (124,125). An endogeneous photosensitizer, riboflavin, can catalyze the generation of active oxygen forms and the photo-oxidation of ascorbate and GSH and this is similarly associated with phototoxicity to lens epithelial cells (104,112,113, 120). Thus, the crystalline lens, a reservoir of reductants such as GSH and ascorbic acid, in addition to transition metal ions or photosensitizers, may become an extremely effective redox-coupled free radical generating system (126-130).

3.5. Oxidative stress, the replicative lifespan of cells, telomere integrity and cellular senescence

The replicative lifespan of primary human cells is telomere dependent ; however, its heterogeneity is not understood (Figure 2c,d). Concerning human ageing, many questions about molecular mechanisms have been addressed using in vitro senescence models derived from normal diploid human cells. The proliferative potential of human primary cells in culture is limited, and extended passaging of such cells leads to a state of terminal growth arrest, referred to as replicative senescence (Figure 4). While the erosion of telomeres, due to the lack of telomerase activity (for recent review, see (131)), has been recognized as a primary cause of replicative cellular senescence, a variety of other events have been identified that trigger premature senescence. Most notably, oxidative stress was found to induce premature senescence in human fibroblasts (132,133), endothelial cells (134,135), and a variety of other cell types (reviewed in ref. (136)).

The mitochondrial theory of ageing (137) suggests a critical role for mitochondrial dysfunction and subsequently increased ROS production as an inducer of ageing and premature senescence. Accordingly, replicative senescence of human diploid fibroblasts (HDF) has been associated with mitochondrial dysfunction and mitochondrial ROS were identified as important players in the senescence response of HDF (138-140). However, mitochondrial dysfunction does not seem to be uniformly responsible for senescence in all cell types. This indicates mitochondrial production of ROS as one of the causes of replicative senescence. By sorting early senescent (SES) cells from young proliferating fibroblast cultures, it has been shown that SES cells have higher ROS levels, dysfunctional mitochondria, shorter telomeres, and telomeric gamma-H2A.X foci (140). The authors propose that mitochondrial ROS is a major determinant of telomere-dependent senescence at the single-cell level that is responsible for cell-to-cell variation in replicative lifespan (140). The intracellular ROS function as signalling molecules and that oxidants play a central role as mediators of cellular senescence. The fact that telomere length correlates with the final inhibition of proliferation under conditions of varied oxidative stress, while the population doubling level does not, suggests that telomere shortening provides the signal for cell cycle exit in senescence. In postmitotic cells, no further telomere shortening occurs (133). However, the sensitivity of terminal restriction fragments to S1 nuclease increases, indicating the accumulation of single-strand breaks in telomeres of nondividing fibroblasts. This effect is found both under normoxic and hyperoxic culture, although it is more pronounced under conditions of higher oxidative stress. It might be speculated that accumulation of single-strand breaks and the resultant loss of distal single-stranded fragments during replication could be a major cause of telomere shortening, possibly more important than incomplete replication per se (133). To determine if increased oxidative stress may contribute to the senescent phenotype, cells were treated with tert-butyl hydroperoxide (tBHP), which is known to increase oxidative stress by decreasing the intracellular glutathione levels. It has been documented that mild tBHP stress induces a phenotype of premature senescence in a subpopulation of the treated cells, which closely resembles the phenotype of naturally senescent human umbilical vein endothelial cells (HUVEC), including growth arrest, senescence-associated beta-gal activity, and apoptotic cell death. These results establish a model of premature senescence for human endothelial cells, suitable to analyze mechanisms of age-associated cell death (134). Furthermore, telomere-shortening rate and cell replicative lifespans can be greatly modified by DNA-damaging oxidative stress (141-142) via a telomere-specific repair deficiency, which causes stress-dependent accumulation of single-strand breaks (145) and accelerates telomere shortening during DNA replication (146). This had led to the suggestion that telomere reduction is not strictly programmed, with telomere length acting as a mere cell-division counting device, but instead that telomeres act as sentinels for cumulative oxidative and/or environmental stress triggering division arrest when the damage burden (detected through telomere length) becomes too great (141). It was hypothesized that accelerated telomere shortening is due to preferential accumulation of oxidative damage in telomeres (145). The data suggest that metabolic time-dependent single-strand degradation is a major cause of telomere shortening. This is supporting the idea that telomere shortening plays an important role in triggering cellular senescence (146). Telomeres in most human cells shorten with each round of DNA replication, because they lack the enzyme telomerase. This is not, however, the only determinant of the rate of loss of telomeric DNA. Oxidative damage is repaired less well in telomeric DNA than elsewhere in the chromosome, and oxidative stress accelerates telomere loss, whereas antioxidants decelerate it. The oxidative stress is an important modulator of telomere loss and telomere-driven replicative senescence is primarily a stress cell response (141) inherent to lens epithelial cells survival and human cataract formation as well.

3.6. Telomeres and Telomerase Activity in Lens Epithelial Cells of Normal and Cataractous Lenses

The adult crystalline lens is lined on its anterior surface by a monolayer of lens epithelial cells (LEC) with diverse replicative potential, including the anterior or central zone, the germinative zone and the equatorial zone. The central LEC are rarely mitotic and generally considered to be quiescent, the germinative LEC have mitotic activity and some of these cells have the potential to divide throughout life and the equatorial LEC terminally differentiate into the lens fiber cells (147-150).

Telomerase activity was found in LEC in all three mammalian species (in canine, feline and murine groups) investigated in the study (61) (but not in human species), confirming that the presence of telomerase activity in these cells is not a canine-specific phenomenon. Telomerase activity was detected in all three LEC regions of the canine lenses (central, germinative, and equatorial) with no significant differences in the level of activity between the different regions . Telomerase activity was absent in canine lens fiber cells, corneal endothelium, corneal epithelium from both the limbal and central regions, and rabbit nonpigmented ciliary epithelium. Surprisingly, telomerase activity was significantly lower in all three regions analysed in canine LEC from dogs less than 1 year of age than in adult dogs (61). Telomerase activity in 23 central capsulotomy specimens collected from naturally occurring canine cataracts were compared to levels in the central lens capsule from normal canine eyes, and surprisingly, significantly higher telomerase activity was found in the cataractous specimens.

Cells that have telomerase activity generally have longer telomeres than cells lacking this activity (151). Since cataractous canine LEC had a higher level of telomerase activity than normal LEC in canine group, it was important to determine if this was reflected in altered telomere lengths in LEC from cataractous canine lenses. In the normal lens capsule samples, there was some heterogeneity in telomere length within each sample as indicated by the number of bands in each lane. However, all normal lens capsules studied and all regions of the LEC had similar banding patterns ranging 4-20 kb, indicating telomere lengths did not differ between the three regions (61). The longest telomere in all normal canine samples measured was consistently 20 kb. Telomeres from cataractous canine capsules also had the same lower range but the upper limits were higher than the normal samples varying 20-24 kb (61). Similar to telomerase activity, pretreatment of normal eyes with topical medications used prior to cataract surgery did not affect telomere lengths. It was not surprising to find telomerase activity in the germinative LEC, as this cell population has the potential to undergo mitosis throughout the life of the canine host (148,149). Cells in the equatorial region of the lens, though not highly mitotic, may retain telomerase activity as the germinative cells migrate into this region. However, once the cells terminally differentiate into fiber cells, they lose telomerase activity, as no activity was found in the fiber cells. Although some post-mitotic cells have telomerase activity (152), many terminally differentiated normal somatic cells do not (153). As previous studies have indicated that central LEC are quiescent and rarely undergo mitosis (148,149) , the presence of telomerase activity in this cell population of mammals was surprising and more difficult to explain. Telomerase negative cells can divide many times in culture, population doublings of 56 and 88 in retinal pigment epithelial cells and foreskin fibroblasts, respectively are possible (154) before telomeres become critically short and cell senescence is triggered. The crystalline lens is exposed to constant nonionizing radiation in the form of ultraviolet light which causes chromosomal damage by inducing DNA strand breaks (155). Damage to genomic DNA is more effectively repaired than damage to telomeric DNA and oxidative damage to DNA in cells without telomerase activity can result in critical shortening of telomeres and cell senescence after just one cell division (145). When cells become senescent they are unable to re-enter the cell cycle and their phenotype dramatically changes (156), they begin to elaborate senescence-associated beta-galactosidase, proteases, extracellular matrix components and inflammatory cytokines. Conversion of LEC to the senescent phenotype is likely to be deleterious to normal lens physiology and transparency. Therefore, the presence of telomerase activity in the central epithelium might be necessary to prevent ultraviolet light induced DNA damage and critical telomere shortening. The loss of telomerase activity upon cell passage and telomere shortening may lead to conversion to the senescent phenotype as evidenced by increasing numbers of cells stained with the senescence marker, beta-galactosidase.

The ability of ultraviolet light to up regulate telomerase activity could have some effects on an age-related increase in activity of this enzyme. Dogs less than 1 year of age had significantly less telomerase activity than adult dogs (61). This suggests that the LEC of young dogs possess a basal level of telomerase activity that increases as the animal matures. It is possible that other local environmental factors, such as H2O2 and other peroxide compounds , could contribute to DNA damage in LEC leading to activation of telomerase activity.

The telomere shortening in rodents may play some role at least as a marker of cell aging in rats although perhaps less of a causal one than in humans (157). In order to examine telomere shortening directly in lens epithelial cells (LECs) in situ, the authors utilized fluorescence in situ hybridization (FISH) of a peptide nuclei acid (PNA) probe to the telomere repeat sequence (TELO-FISH). Although it is not clear whether such moderate telomeric erosion can limit cell division in rodent LECs, the telomeric shortening correlated well with previous studies demonstrating reduced clonal replicative potential, and reduced rates of in vivo DNA replication in LECs from old rodents and a delay in this attenuation in animals on chronic caloric restriction (157). Examination of LECs in each of nine young and nine old ad lib fed (AL), and nine old calorically restricted (CR) rat lenses, demonstrated that rat LEC telomeres were shortened by 21% in old AL fed rats relative to young controls (P< 0.01) and that CR reduced this loss to 12% (P< 0.05) (157). This suggests a possible relationship between telomeric shortening, loss of replicative potential in LECs, and cataract appearance in rodents. Oxidative or other damage to the telomeric DNA appears to act synergistically increasing the probability of capping failure and cell senescence even with only moderate average shortening (144,158,159). Numerous genes regulate telomerase activity within the cell (160) but the process is quite complex and currently not well understood. Perhaps telomerase is up regulated in cataractogenesis in dogs as a protective response to DNA damage, as it has been shown that there is significant damage to DNA in LEC from human cataractous lenses compared to normal lenses (161).

There has been some time ago a renewed interest in the association between DNA damage to the human lens epithelium and the development of lens opacities in human patients (161) . In approximately 50% of the cataractous samples analyzed, the proportion of cells containing DNA single strand breaks was significantly higher than in control lenses. It is important that no relationship between age and DNA damage was noted. These findings are consistent with the hypothesis that in some human patients with cataract, DNA damage in the lens epithelial cell population may be related to the development of lens fiber cell opacity (161). The possible relationships and effect for these phenomena are suggestive for oxidative damage, telomere shortening and loss of replicative capacity and corresponding to senescent phenotype alteration of gene expression patterns contributing to human age-related cataract formation, in that order.

In the recent study (162) the authors reported that human telomerase reverse transcriptase (hTERT) displays additional functions beyond telomere synthesis. They have demonstrated that hTERT introduced into Bovine lens epithelial cells (LECs) can suppress differentiation. Furthermore, the authors provided the evidence (162) that hTERT can regulate the RAS/RAF/MEK/ERK pathway to mediate the suppression of bovine lens epithelial cell differentiation. This study provides evidence that hTERT regulates both proliferation and differentiation in eukaryotes. The results of another study suggest that hTERT, when overexpressed in human lens epithelial cells, accelerates cell growth rate through regulation of RB/E2F pathway and possibly other genes (163).

Among the human, bovine, and rabbit lenses examined, only the central epithelium from the 6-month rabbit lens displayed telomerase activity (164). In both transparent and cataractous human lenses, hTERT activity and expression were not detected. However, the template RNA was present in both types of human lenses (164). The telomeres found in transparent human lenses were approximately 1 kb longer than those in cataractous human lenses. These results suggest the possibility that telomere shortening is associated with human cataractogenesis. The primary cultures and later passages of HLECs also displayed no detectable telomerase activity. Introduction of hTERT cDNA into HLECs followed by G418 selection yielded a stable line of HLECs expressing hTERT. In this line, hTERT has supported normal growth after 48 population doublings and also enhanced antiapoptotic activity against oxidative stress (164). hTERT introduced into HLECs prevents replicative senescence through telomere synthesis. The hTERT-transfected cells with normal growth have a maximum telomere length of approximately 13 kb. Shortening of this telomere length to a certain degree signals cellular senescence, as observed in vector-transfected HLECs, which have a maximum telomere length of approximately 10 kb. Thus, HLECs use a telomerase-dependent mechanism to maintain their telomere stability (164).

3.7. N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human eyes or visually disabling eye diseases as well as systemic health conditions

During the adult years, the increased visual demands of our technological society bring about the need for regular optometric care (Figures 5a,b) (165,166). While the incidence of ocular disease is low for young adults, vocational and recreational visual demands are significant. To maintain visual efficiency, productivity, and optimum eye health, periodic examinations are recommended.

Adults, beginning in their early to mid-forties, can experience changes in their ability to see clearly at close distances. This normal aging change in the eye's focusing ability will continue during the forties and fifties. In addition, increases in the incidence of eye health problems occur during these years. Individuals age 61 or older have an increasing risk for the development of cataracts, glaucoma and macular degeneration and other sight threatening or visually disabling eye conditions as well as systemic health conditions. Therefore, annual eye examinations are recommended. At risk are individuals diagnosed with diabetes or hypertension, or who have a family history of glaucoma or cataracts, and those taking systemic medications with ocular side effects or those with other health concerns or conditions.

Carnosine (beta-alanyl-L-histidine) and related compounds are natural constituents of excitable tissues possessing diverse biological activities (167,168). The level of carnosine in tissues is controlled by a number of enzymes transforming carnosine into other carnosine related compounds, such as carcinine, N-acetylcarnosine, anserine or ophidine (by decarboxylation, acetylation or methylation, respectively) or its cleavage into the amino acids, histidine and β-alanine. Hydrolysis is mainly due to tissue carnosinase (EC 3.4.13.3) which is widely distributed among different tissues (169,170) or serum carnosinase (EC 3.4.13.20), found in brain and blood plasma of primates and humans (171,172). Both carnosine and N-acetylcarnosine compounds are found primarily in the heart and skeletal muscles and in the brain. We have found appreciable levels of L-carnosine in transparent human lenses which are markedly depleted in mature cataracts (173). The concentration of carnosine in transparent crystalline lenses detected was about 25 μM. At different stages of cataract development, the level of carnosine fell, reaching about 5 μM (173). Carnosine has been proven to scavenge reactive oxygen species (ROS) as well as alpha-beta unsaturated aldehydes formed from peroxidation of cell membrane fatty acids during oxidative stress (174-176). It can oppose glycation (177,178) and it can chelate divalent metal ions . The important studies have produced clinical and experimental evidence of beneficial effects of N-acetylcarnosine in treating cataracts of the eyes, these and other ophthamological benefits have been proven (2,179-186). Research with N-acetylcarnosine (NAC) demonstrates that it is effective not only in preventing cataracts but also in treating them. NAC has been shown to improve vision by partially reversing the development of the cataract, thus increasing the transmissivity of the lens to light (181).

One of the obscure aspects of the carnosine physiological role is the biological significance of the enzymatic metabolism of carnosine or its derivatives in tissues. We found that , in order to change the antioxidant status, tissue enzymes can modify the NAC prodrug molecule and that deacetylation increases in vivo the resistance of lens tissues and its cells to oxidative stress. 1% N-acetylcarnosine (Figure 5a) is a universal bioactivating antioxidant for vision in the developed and patented drug delivery system lubricant eye drop formulations containing mucoadhesive cellulose-based compound combined with corneal absorption promoters. Its topical administration delivers pure L-carnosine and allows its increased intraocular absorption into the aqueous humor surrounding the lens, enabling significant improvements in anti-cataract drug efficacy and the minimization of side-effect from either local or systemic drug absorption/bioavailability to the eye, and also creates optimization effects in the number of ocular degenerative age-dependent disorders (182). The formulation was also found to be non-irritant and well tolerable. The developed system can be a viable alternative to conventional eye drops for the treatment of various ocular diseases and is suitable for clinical application. N-acetylcarnosine prodrug and codrug ophthalmic formulations applied topically to the eye and moreover, its controlled time released ophthalmic ingredient L-carnosine exerts anti-glycation, bioactivating antioxidant properties in the lens and cornea as a scavenger of lipid peroxides, singlet oxygen and OH� radicals and provides the spatial aspects of intracellular pH regulation (126,181,183).

3.8. Intraocular transcorneal and systemic absorption of L-carnosine from N-acetylcarnosine ocular drug delivery system: Suitable molecular therapeutic interventions and visual sensory signaling responses

The provided studies with N-acetylcarnosine ophthalmic prodrug confirmed the increased intraocular uptake of L-carnosine active ingredient in the aqueous humor (186-189).

Histidyl compounds of aqueous humor have been examined by reverse phase analytical HPLC (Figure 6) as used in separation of imidazole-containing amino acids and dipeptides described earlier (187-189). Amino acids can be detected by the absorbance of carboxylate (~ 200 nm) and peptides by absorbance of carboxylate and the peptide bond (200-220 nm). Chromatograms of solutions of L-carnosine and its putative N-acetyl derivative are well separated. The elution order of the compounds was compared to a predicted order based upon their relative hydrophobicities as outlined by Rekker (190). Peaks were unequivocally identified by comparison of their retention times to those of the authentic standard compounds or of putative acetylated compound run singly . Tests for specific chemical reactivity (191) provided additional evidence for the identification of L-carnosine and N-acetylcarnosine.

Due to its relative hydrophobicity compared to L-carnosine, NAC might cross the cornea of the treated eye gradually and maintain longer the concentration of the active principle (L-carnosine) reaching the aqueous humor. The HPLC pattern of an extract of the aqueous humor obtained 30 min after instillation to the rabbit eye of ophthalmic formulation containing 1% NAC, lubricants carboxymethylcellulose, glycerine and preservative benzyl alcohol in the borate buffer confirms that the peak characteristic of L-carnosine has a concentration and a retention time (3.225 min) clearly distinct from N-acetylcarnosine (6.0 min) and basically different from the dead time of the column (3.0 min) (Figure 6). This identified peak of L-carnosine quantified and integrated by the data processor showed that virtually all N-acetylcarnosine after the overall extraction efficiency is converted into the L-carnosine compound with a retention time of 3.225 min (Figure 6). The data on the L-carnosine-related product were blanked with the control placebo data applied to the paired eyes of the animals. The mean ratio of L-carnosine (C) / (NAC) relevant to the L-carnosine release in the aqueous humor 30 min after instillation of Formulation A (Can-C TM) with 1% N-acetylcarnosine into the rabbit eye corresponded to C/NAC=6.64�0.06 (n =8, where n =number of the examined treated rabbit eyes; only right eyes were treated). In the control placebo formulation-treated eyes the same indices could not be quantified at statistically significant rate. Concentrations of imidazole products in the aqueous humor corresponded to those of intact rabbit eyes and refer to baseline values of L-carnosine 0.19� 0.10 μg/ml related products variously detected in extracts from normal animals.

Our data demonstrate that topical administration of pure L-carnosine (1% solution) to the rabbit eye (instillation, subconjunctival injection) does not lead to accumulation of this natural compound in the aqueous humor over 30 min in concentration exceeding that in the placebo-treated matched eyes, and its effective concentration is exhausted more rapidly (189,192). In another aspect, the data demonstrate the prospects of applications of an ophthalmic composition comprising NAC, or its pharmacologically acceptable salt in combination with a cellulose compound to treat the eye complex of symptoms. This complex of symptoms may have an oxidative component in their genesis, such as senile cataract, glaucoma, inflammation or diabetic ocular complications. The topical administration of N-acetylcarnosine in the developed and patented lubricant eye drop formulation delivers pure L-carnosine and allows its increased intraocular absorption into the aqueous humor surrounding the lens, thus enabling significant improvements in anti-cataract efficacy Figs. 6,7 (126-130).

The important pharmacokinetic observation activities of the tested ophthalmic formulation Can-C TM including 1% N-acetylcarnosine and lubricant carboxymethylcellulose relate to the accumulation of L-carnosine in the aqueous humor of the contralateral rabbit eyes after 30 min of instillation of the medication to the tested rabbit eyes. The detected measure of L-carnosine in the aqueous humor of the contralateral untreated eyes corresponded to 1.45 � 0.08 μg/ml (n=9). The data indicate that intraocular route for the administered medication includes (at least partially) a systemic drug absorption in the preferred intraocular site of L-carnosine released from 1% N-acetylcarnosine ophthalmic prodrug enhanced with the addition into the ophthalmic formulation of a cellulose derivative, i.e. carboxymethylcellulose (bioadhesive and absorption enhancer) that is also used as a mucoadhesive carrier for the patented ocular drug, due to its ability to coat the cornea and remain on the eye for a longer time. This route of systemic absorption of biologically active compound avoids the first-pass effect normally observed after oral presentation of a compound, and the pharmacological sequelae resemble those seen after an intravenous administration. This pharmacokinetic phenomenon have been given in clinical situations with topical administration of anti-glaucoma medicines to the eye , since the systemic effects of drugs such as timolol can be quite pronounced (193).

The systemically absorbed L-carnosine released from the topically administered to the eyes 1% N-acetylcarnosine ophthalmic prodrug Can-C TM as lubricant eye drops, is acting not only as a radical scavenger but also represents a possible neurotransmitter-like molecule that regulates neuronal functions such as hypothalamic control of the autonomic nervous system. CN2 (CNDP2) is a cytosolic enzyme that can hydrolyze carnosine to yield l-histidine and beta-alanine. CN2-immunoreactivity is highly concentrated in neuronal cells in the dorsal part of the tuberomammillary nucleus of the posterior hypothalamus (194). Since the tuberomammillary nucleus is the exclusive origin of histaminergic neurons, further investigations were focused, whether CN2 is present in the histaminergic neurons. It was found that CN2-immunoreactivity was colocalized with that of histidine decarboxylase, which is the key enzyme for histamine biosynthesis specifically expressed in the histaminergic neurons of the tuberomammillary nucleus (194). These results clearly indicate that CN2 is highly expressed in the histaminergic neurons in the tuberomammillary nucleus, implying that systemically absorbed L-carnosine released from the Can-C TM ophthalmic formulation topically administered to the eyes serves as a metabolic source to supply histidine and activates histaminergic neurons for histamine synthesis (Figure 8). Axons of the tuberomammillary nucleus project primarily to the cerebral cortex, thalamus, basal ganglia, basal forebrain, and hypothalamus. Tuberomammillary activation usually results in a rapid and significant increase in the amplitude of baseline activity and visual responses in lateral geniculate nucleus (LGN) neurons (195). Tuberomammillary activation causes a small phase lag in the visual response that is similar at all spatial frequencies, consistent with the induced shift from burst to tonic firing mode. These results indicate a significant histaminergic effect of L-carnosine on LGN thalamocortical cells, with no clear effect on thalamic inhibitory neurons.

3.9. Human Lens Telomeres as a Prospective Biological Target for N-acetylcarnosine Ophthalmic Indications

In this work, we originally propose that the existence of shortened telomeres in the human lens epithelial cells is the molecular clock that triggers cellular senescence phenotype during aging and cataract progression and is the result of oxidative attack to the lens by phospholipid hydroperoxides present in the aqueous humor and lens cellular membrane structures in the lack of efficacy of the antioxidant protection in the lens towards these damaging oxidant promoters (Figure 2a) (196). The cumulative results from the literature demonstrated that carnosine at physiological concentration might remarkably reduce the rate of telomere shortening in the continuously surviving lens cells subjected to oxidative stress induced by phospholipid hydroperoxides in the lack of efficient antioxidant lens protection (196-200). Carnosine and related dipeptides have been shown to prevent peroxidation of model membrane systems leading to the suggestion that they represent water-soluble counterparts to lipid-soluble antioxidants such as alpha-tocopherol in protecting cell membranes from oxidative damage (189).

Other roles ascribed to these dipeptides in ophthalmics include actions as neurotransmitters, modulation of enzymic activities, chelation of heavy metals and transition metal ions , the inhibition of nonenzymic glycosylation of proteins (transglycating activities) (126-130). We proposed a deglycation system involving removal, by transglycation of sugar or aldehyde moieties from the Schiff bases by ophthalmic aldehyde scavenger L-carnosine derived from its ocular bioactivating sustained release prodrug 1% N-acetylcarnosine (NAC) lubricant eyedrops containing a mucoadhesive cellulose compound combined with corneal absorption promoters in drug delivery system (126).

Carnosine attenuates the development of senile features when used as a supplement to a standard diet of senescence accelerated mice (SAM) devoid of serum carnosinase activity (201). Its effect is apparent on physical and behavioral parameters and on average life span. A striking anti-senescence effect of carnosine was demonstrated by McFarland and Holliday (197-199). They showed that human diploid fibroblasts grown in 20 mM carnosine had an extended lifespan, both in population doublings (PDs) and chronological time. The dipeptide L-carnosine had beneficial effects on cultured human fibroblasts. Physiological concentrations in standard media prolong their in vitro lifespan and strongly reduce the normal features of senescence. Late passage cells in normal medium were rejuvenated when transferred to medium containing carnosine, and became senescent when carnosine was removed (197). Neither D-carnosine, (beta-alanyl-D-histidine), homocarnosine, anserine, nor beta-alanine had the same effects as carnosine on human fibroblasts.

In the recent work (200), the authors studied the effect of carnosine on a human fetal lung fibroblast strain (HPF), which was either kept in a continuously proliferating or proliferation-inhibited state. The results indicate that carnosine can reduce telomere shortening rate possibly by protecting telomere from damage. Cells continuously grown in 20 mM carnosine exhibited a slower telomere shortening rate and extended lifespan in population doublings. When kept in a long-term nonproliferating state, they accumulated much less damages in the telomeric DNA when cultured in the presence of carnosine. The authors suggest that the reduction in telomere shortening rate and damages in telomeric DNA made an important contribution to the life-extension effect of carnosine (200).

In our review we propose the effects of carnosine on telomeres of the human lens epithelial cells during aging and cataract formation based on the established clinical efficacy of L-carnosine ophthalmic prodrug N-acetylcarnosine to partially reverse and prevent human cataracts in clinics (Figure 7) (126-130;179-185).

3.10. The clinical effects of N-acetylcarnosine ophthalmic prodrug through protections from telomere attrition and shortening: prevention and reversal of cataracts, basic preventive health care

The data of visual functions (visual acuity, glare sensitivity) in older adult subjects and older subjects with cataract treated with 1% NAC showed significant improvement as compared, by contrast with the control group which showed generally no improvement in visual functions, with no difference from baseline in visual acuity and glare sensitivity readings (126-130;179-185). In most of the patients treated, study treatment was well tolerated and no ocular or systemic adverse events were reported. Use of NAC to treat cataract and aging lens can lead to diminishing of light scattering units in the lens which raise glare effect, probably by prevention of the oxidative modification of crystallins and utilization of lipid peroxides (126-130;179-185).The present investigation indicates that carnosine derived from N-acetylcarnosine ophthalmic prodrug can preserve telomere structures in the lens epithelial cells, mitochondrial function, cell viability, and ATP levels in human lens cells during oxidative stress. Although the precise mechanism responsible for protection by the carnosine against oxidative stress remains to be determined, the ability of non-hydrolized carnosine, to protect against peroxide toxicity indicates that this type of biological activity is likely to be mediated through scavenging effect of carnosine towards toxic aldehydes and phospholipid hydroperoxide compounds (lipid peroxidation products) inducing shortening of telomeres in the lens epithelial cells. Carnosine promotes the protection of normal cells from acquiring phenotypic characteristics of cellular senescence switching human lens into the process of ageing and cataractogenesis.

Aging is postulated to be a telomere-shortening process, and may be a phenomenon in which some telomeres have already undergone partial shortening in early individual development. The latter situation would result in these shortened telomeres undergoing further shortening during the individual's lifetime, leading to abnormally accelerated imbalances in functioning of neuroendocrine and neurotrophic cells and provoking neurodegenerative events. If aging is an intrinsically programmed process and if it is engendered by a growing deficit of telomeric activity, then identification of telomere-associated processes, and their artificial reproduction and therapeutic usage targeting telomers and their products would open new perspectives in overcoming age-related diseases that currently appear to be incurable (202).The systemic absorption of carnosine released from the ophthalmic prodrug N-acetylcarnosine can have an appropriate therapeutic influence on the lifelong clock which is regulated by the shortening of telomere DNA during ageing and age-related disorders in postmitotic neurons of the hypothalamus. Shortening of these DNA sequences occurs in humans on a monthly basis and is controlled by release of growth hormone discharged from the anterior pituitary directly into the hypothalamus via local blood vessels (202).

3.11. Prevention of complications of cataract surgery with N-acetylcarnosine ophthalmic prodrug: targeting secondary cataracts through modulation of cell senescent behavior

Once a clouded lens develops, surgical removal is still the usual remedy. Each year about 1.5 million cataract operations are performed, making it the most common operation in the country in people over 65 (Reviewed in Refs. 127,130).

Problems after cataract surgery are rare, but they can occur. These problems can include infection, bleeding, inflammation (pain, redness, swelling), loss of vision, double vision and high or low eye pressure . The following side effects are documented : retinal detachment, cystoid macula edema, posteriorly dislocated lens material, endophthalmitus, choroidal hemorrhage, secondary cataracts (Reviewed in Refs. 3,130, 181).Often the eye tissue that endoses the intraocular lens (IOL) becomes cloudy and may blur the vision of the eye subjected to cataract surgery. This condition is called after-cataract (secondary cataract). An after-cataract can develop months or years after cataract surgery. Residual lens epithelial cells (LECs) undergo fibrous proliferation after cataract surgery, resulting in capsular fibrosis (Reviewed in Ref. 203).

3.11.1. Secondary cataracts (Posterior Capsular Opacification) and their treatments

About 30% of patients who undergo extracapsular cataract surgery develop a secondary "after-cataract" called posterior capsular opacification. Posterior capsular opacification generally occurs because of the following events:- After surgery, there are still some natural lens cells left behind that proliferate on the back of the capsule. The capsule gradually becomes cloudy and interferes with clear vision the same way the original cataract did.

According to a 2001 study, the probability of developing a secondary cataract was 6% at one year, 15% at two years, 23% at three years, and 38% at nine years (Reviewed in Refs. 127,130). The risk is lower with phacoemulsification. Secondary cataracts are more likely to occur in younger patients, in those with diabetes, or when cataract surgery is combined vitrectomy (clearance of debris from the fluid in the eye). The appearance of a secondary cataract constitutes the most common complication of cataract surgery since the advent of phacoemulsification. Prevention is today one of the crucial challenges of research in ophthalmology.

3.11.2. Treatment for Posterior Capsular Opacification

The standard treatment is laser surgery known as a YAG capsulotomy. (Capsulotomy means cutting into the capsule, and YAG is an abbreviation of yttrium aluminum garnet, the laser most often used for this procedure). However, laser surgery carries its own risks and possible complications, similar to those of cataract surgery itself, and can also lead to poorer vision or blindness. About 1% of laser surgery patients develop a detached retina, which is much higher than the risk from the original cataract surgery.

The present benefits of N-acetylcarnosine ophthalmic therapeutic modality relates to a method for treatment or prevention of secondary cataract, comprising contacting the surface of the eye with an effective amount of a therapeutically active and physiologically acceptable N-acetylcarnosine combined with the cellulose compound releasing carnosine in the aqueous humor that prevents the senescent phenotype of residual germinative lens epithelial cells in in the equatorial regions of the lens capsule after cataract surgery.

We have developed a drug-sustained N-acetylcarnosine delivery system releasing carnosine in anterior chamber of the eye. This system targets the goal of combining advantageous pharmacological properties of carnosine with the ability to interfere on the epithelial cellular processes of secondary cataract. Clinical evaluation based on biomicroscopy and histology showed a lesser reaction of secondary cataract treated in eyes with the N-acetylcarnosine ophthalmic prodrug. The decrease in secondary cataract reaction in cases of N-acetylcarnosine treatment of after-cataract demonstrated the advantages of its pharmacological effect (Figure 3). The pharmacological and theoretical concept of a drug-sustained delivery system seems attractive and thus calls for further evaluation of cellular telomeres modulators and of cell behavior.

4. SUMMARY AND PERSPECTIVE

Although human cataractogenesis is associated with aging, direct evidence of lens epithelial cellular senescence and the mechanism of senescence associated with chronic oxidative stress and accompanying ocular and systemic abnormalities or diseases during aging and cataractogenesis is lacking. This work demonstrates that oxidants induced premature senescence in human lens epithelial cells, with accelerated telomere shortening and reduced telomerase activity (although many human lenses lack detectable telomerase activity (164)). We conclude that human cataractogenesis is characterized by senescence of lens cells, accelerated by oxidative stress-induced DNA damage, inhibition of telomerase and marked telomere shortening. Prevention of cellular senescence with ophthalmic prodrug N-acetylcarnosine may be a novel therapeutic target in a management of cataract, basic preventive health care and in arresting of after-cataract following extracapsular cataract extraction.

5. ACKNOWLEDGEMENTS

This work was planned, organized, and supported by Innovative Vision Products, Inc. (County of New Castle, DE, USA), by Russian Foundation for Basic Research (grant 09-04-01071a and Federal Agency for Education (State contract P1293). Innovative Vision Products, Inc. is a holder of the worldwide patent (including PCT International Publication Number WO 2004/028536 A1) for the application of N-acetylcarnosine for the Treatment of ophthalmic disorders, including cataracts as well as (PCT International Publication Number WO 2004/064866 PCT/JP2004/000351) protecting the described in the article therapeutic applications. Innovative Vision Products Inc. is a Pharmaceutical and Nanotechnology Development Company with a focus on innovative chemical entities, drug delivery systems, and unique medical devices to target specific biomedical applications. Over the last decade IVP has developed a track record in developing these technologies to effectively address the unmet needs of specific diseased populations. The authors report the interest in the Intellectual Property and marketing of the described modalities protected with the patents. The authors bear primary responsibility for accuracy of statements made in this document.

7. REFERENCES

  1. Spector A. Review: Oxidative stress and disease. J Ocul Pharmacol Ther., Apr;16 (2):193-201 (2000).

    doi:10.1089/jop.2000.16.193


  2. http://dx.doi.org/10.1089/jop.2000.16.193

    2. Kisić B, Mirić D, Zorić L, Dragojević I, Stolić A. (Role of lipid peroxidation in pathogenesis of senile cataract) (Article in Serbian) Vojnosanit Pregl. , May;66 (5):371-5 (2009). (PubMed: 19489472)

    3. Babizhayev MA, Deyev AI, Yermakova VN, Brikman IV, Bours J. Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes. Drugs R D., 5 (3):125-39 (2004). (PubMed: 15139774)
    doi:10.2165/00126839-200405030-00001
    http://dx.doi.org/10.2165/00126839-200405030-00001

    4. Borchman D, Yappert MC. Age-related lipid oxidation in human lenses. Invest Ophthalmol Vis Sci., May;39 (6):1053-8 (1998). (PubMed: 9579487)

    5. Sawada H, Fukuchi T, Abe H. Oxidative stress markers in aqueous humor of patients with senile cataracts. Curr Eye Res., Jan;34 (1):36-41 (2009). (PubMed: 19172468)
    doi:10.1080/02713680802500960
    http://dx.doi.org/10.1080/02713680802500960

    6. Maurya OP, Mohanty L, Bhaduri G, Chandra A. Role of anti-oxidant enzymes superoxide dismutase and catalase in the development of cataract : study of serum levels in patients with senile and diabetic cataracts. J Indian Med Assoc., Jul;104 (7):394, 396-7 (2006). (PubMed: 17240813)

    7. Saadat M, Farvardin-Jahromi M, Saadat H. Null genotype of glutathione S-transferase M1 is associated with senile cataract susceptibility in non-smoker females. Biochem Biophys Res Commun. , Jul 9;319 (4):1287-91 (2004). (PubMed: 15194507)
    doi:10.1016/j.bbrc.2004.05.121
    http://dx.doi.org/10.1016/j.bbrc.2004.05.121

    8. Saadat M, Farvardin-Jahromi M. Occupational sunlight exposure, polymorphism of glutathione S-transferase M1, and senile cataract risk. Occup Environ Med., Jul;63 (7):503-4. Epub 2006 Mar 21 (2006). (PubMed: 16551760)
    doi:10.1136/oem.2005.022343
    http://dx.doi.org/10.1136/oem.2005.022343

    9. Sreenivas V, Prabhakar AK, Badrinath SS, Fernandez T, Roy IS, Sharma T, Shah B. A rural population based case-control study of senile cataract in India. J Epidemiol., Nov;9 (5):327-36 (1999). (PubMed: 10616266)

    10. Tissié G, Flangakis S, Missotten L, D'Hermies F, de Laey JJ, Bourgeois H, Zenatti C, Hermet JR, Rigeade MC, Bonne C. Antioxidant activity of plasma from subjects with and without senile cataract. Doc Ophthalmol. ,83 (4):357-61 (1993). (PubMed: 8223105)
    doi:10.1007/BF01204338
    http://dx.doi.org/10.1007/BF01204338

    11. Javitt JC, Taylor HR. Cataract and latitude. Doc Ophthalmol. ,88 (3-4):307-25 (1994-1995). (PubMed: 7634999)
    doi:10.1007/BF01203684
    http://dx.doi.org/10.1007/BF01203684

    12. Bhuyan DK, Huang X, Kuriakose G, Garner WH, Bhuyan KC. Menadione-induced oxidative stress accelerates onset of Emory mouse cataract in vivo. Curr Eye Res., Jun;16 (6):519-26 (1997). (PubMed: 9192159)
    doi:10.1076/ceyr.16.6.519.5070
    http://dx.doi.org/10.1076/ceyr.16.6.519.5070

    13. Bhuyan DK, Bhuyan KC. Assessment of oxidative stress to eye in animal model for cataract. Methods Enzymol. ,233:630-9 (1994). (PubMed: 8015495)
    doi:10.1016/S0076-6879%2894%2933066-2
    http://dx.doi.org/10.1016/S0076-6879%2894%2933066-2

    14. Bhuyan KC, Bhuyan DK, Chiu W, Malik S, Fridovich I. Desferal-Mn (III) in the therapy of diquat-induced cataract in rabbit. Arch Biochem Biophys. , Aug 1;288 (2):525-32 (1991). (PubMed: 1654836)
    doi:10.1016/0003-9861%2891%2990230-G
    http://dx.doi.org/10.1016/0003-9861%2891%2990230-G

    15. Babizhayev MA, Deyev AI. Lens opacity induced by lipid peroxidation products as a model of cataract associated with retinal disease. Biochim Biophys Acta., Jul 17;1004 (1):124-33 (1989). (PubMed: 2742866 )
    doi:10.1016/0005-2760%2889%2990222-1
    http://dx.doi.org/10.1016/0005-2760%2889%2990222-1

    16. Manikandan R, Thiagarajan R, Beulaja S, Chindhu S, Mariammal K, Sudhandiran G, Arumugam M. Anti-cataractogenic effect of curcumin and aminoguanidine against selenium-induced oxidative stress in the eye lens of Wistar rat pups: An in vitro study using isolated lens. Chem Biol Interact. , Oct 7;181 (2):202-9. Epub 2009 May 27 (2009). (PubMed: 19481068 )
    doi:10.1016/j.cbi.2009.05.011
    http://dx.doi.org/10.1016/j.cbi.2009.05.011

    17. Olofsson EM, Marklund SL, Behndig A. Enhanced diabetes-induced cataract in copper-zinc superoxide dismutase-null mice. Invest Ophthalmol Vis Sci. , Jun; 50 (6):2913-8. Epub 2009 Mar 25 (2009). (PubMed: 19324844 )
    doi:10.1167/iovs.09-3510
    http://dx.doi.org/10.1167/iovs.09-3510

    18. Rooban BN, Lija Y, Biju PG, Sasikala V, Sahasranamam V, Abraham A. Vitex negundo attenuates calpain activation and cataractogenesis in selenite models. Exp Eye Res. , Mar;88 (3):575-82. Epub 2008 Dec 6 (2009). (PubMed: 19094987)
    doi:10.1016/j.exer.2008.11.020
    http://dx.doi.org/10.1016/j.exer.2008.11.020

    19. Hegde KR, Kovtun S, Varma SD. Induction of ultraviolet cataracts in vitro: prevention by pyruvate. J Ocul Pharmacol Ther. , Oct;23 (5):492-502 (2007). (PubMed: 17900232)
    doi:10.1089/jop.2007.0038
    http://dx.doi.org/10.1089/jop.2007.0038

    20. Raju TN, Kumar CS, Kanth VR, Ramana BV, Reddy PU, Suryanarayana P, Reddy GB. Cumulative antioxidant defense against oxidative challenge in galactose-induced cataractogenesis in Wistar rats. Indian J Exp Biol. , Sep;44 (9):733-9 (2006). (PubMed: 16999028)

    21. Geraldine P, Sneha BB, Elanchezhian R, Ramesh E, Kalavathy CM, Kaliamurthy J, Thomas PA. Prevention of selenite-induced cataractogenesis by acetyl-L-carnitine: an experimental study. Exp Eye Res. , Dec;83 (6):1340-9. Epub 2006 Sep 8 (2006). (PubMed: 16962580)
    doi:10.1016/j.exer.2006.07.009
    http://dx.doi.org/10.1016/j.exer.2006.07.009

    22. Kocer I, Taysi S, Ertekin MV, Karslioglu I, Gepdiremen A, Sezen O, Serifoglu K. The effect of L-carnitine in the prevention of ionizing radiation-induced cataracts: a rat model. Graefes Arch Clin Exp Ophthalmol. , Apr;245 (4):588-94. Epub 2006 Aug 17 (2007). (PubMed: 16915402 )
    doi:10.1007/s00417-005-0097-1
    http://dx.doi.org/10.1007/s00417-005-0097-1

    23. Babizhayev MA. Accumulation of lipid peroxidation products in human cataracts. Acta Ophthalmol (Copenh). , Jun;67 (3):281-7 (1989). (PubMed: 2763816)
    doi:10.1111/j.1755-3768.1989.tb01872.x
    http://dx.doi.org/10.1111/j.1755-3768.1989.tb01872.x

    24. Fan X, Zhang J, Theves M, Strauch C, Nemet I, Liu X, Qian J, Giblin FJ, Monnier VM. Mechanism of lysine oxidation in human lens crystallins during aging and in diabetes. J Biol Chem. 284 (50): 34618-27 (2009). (PubMed: 19854833)
    doi:10.1074/jbc.M109.032094
    http://dx.doi.org/10.1074/jbc.M109.032094

    25. Yildirim Z, Yildirim F, Ucgun NI, Kilic N. The evaluation of the oxidative stress parameters in nondiabetic and diabetic senile cataract patients. Biol Trace Elem Res. , May;128 (2):135-43. Epub 2008 Nov 4 (2009). (PubMed: 18982249)
    doi:10.1007/s12011-008-8258-9
    http://dx.doi.org/10.1007/s12011-008-8258-9

    26. Linetsky M, Shipova E, Cheng R, Ortwerth BJ. Glycation by ascorbic acid oxidation products leads to the aggregation of lens proteins. Biochim Biophys Acta. , Jan;1782 (1):22-34. Epub 2007 Oct 16 (2008). (PubMed:18023423 )
    doi:10.1016/j.bbadis.2007.10.003
    http://dx.doi.org/10.1016/j.bbadis.2007.10.003

    27. Huang L, Yappert MC, Miller JJ, Borchman D. Thyroxine ameliorates oxidative stress by inducing lipid compositional changes in human lens epithelial cells. Invest Ophthalmol Vis Sci. , Aug;48 (8):3698-704 (2007). (PubMed: 17652741)
    doi:10.1167/iovs.06-0908
    http://dx.doi.org/10.1167/iovs.06-0908

    28. Fan X, Reneker LW, Obrenovich ME, Strauch C, Cheng R, Jarvis SM, Ortwerth BJ, Monnier VM. Vitamin C mediates chemical aging of lens crystallins by the Maillard reaction in a humanized mouse model. Proc Natl Acad Sci U S A. , Nov 7;103 (45):16912-7. Epub 2006 Oct 30 (2006). (PubMed: 17075057)
    doi:10.1073/pnas.0605101103
    http://dx.doi.org/10.1073/pnas.0605101103

    29. Barros PS, Safatle AM, Queiroz L, Silva VV, Barros SB. Blood and aqueous humour antioxidants in cataractous poodles. Can J Ophthalmol. , Feb;39 (1):19-24 (2004). (PubMed: 15040610)

    30. Donma O, Yorulmaz E, Pekel H, Suyugül N. Blood and lens lipid peroxidation and antioxidant status in normal individuals, senile and diabetic cataractous patients. Curr Eye Res. , Jul;25 (1):9-16 (2002). (PubMed: 12518238)
    doi:10.1076/ceyr.25.1.9.9960
    http://dx.doi.org/10.1076/ceyr.25.1.9.9960

    31. Hashim Z, Zarina S. Antioxidant markers in human senile and diabetic cataractous lenses. J Coll Physicians Surg Pak. , Oct;16 (10):637-40 (2006). (PubMed: 17007750 )

    32. Ma W, Nunes I, Young CS, Spector A. Catalase enrichment using recombinant adenovirus protects alphaTN4-1 cells from H (2)O (2). Free Radic Biol Med. , Jan 15;40 (2):335-40. Epub 2005 Oct 17 (2006). (PubMed: 16413415)
    doi:10.1016/j.freeradbiomed.2005.08.032
    http://dx.doi.org/10.1016/j.freeradbiomed.2005.08.032

    33. Horwitz J, Jaffe N. Anatomy and embryology. In Textbook of Ophthalmology 3, Lens and Cataract (Podos, S. M., and Yanoff, M., eds) Cower Medical Publishing, New York (1992).

    34. Harding JJ & Crabbe MJ . The lens: development, proteins, metabolism and cataract. In The Eye, (Davson, H., ed) Vol. lB. Academic Press, Orlando, Florida (1984).

    35. Spector A, Wang G-M, Wang R-R, Li W-C, Kuszak JR. A brief photochemically-induced oxidative insult causes irreversible lens damage and cataract I: transparency and epithelial cell layer. Exp Eye Res.,60 (5):471-481 (1995). (PubMed:7615013 )
    doi:10.1016/S0014-4835%2805%2980062-4
    http://dx.doi.org/10.1016/S0014-4835%2805%2980062-4

    36. Reddy VN, Lin LR, Ho YS, Magnenat JL, Ibaraki N, Giblin FJ, Dang L. Peroxide-induced damage in lenses of transgenic mice with deficient and elevated levels of glutathione peroxidase. Ophthalmologica. ,211 (3):192-200 (1997). (PubMed: 9176901)

    37. Spector A, Yang Y, Ho YS, Magnenat JL, Wang RR, Ma W, Li WC. Variation in cellular glutathione peroxidase activity in lens epithelial cells, transgenics and knockouts does not significantly change the response to H2O2 stress. Exp Eye Res. , May;62 (5):521-40 (1996). (PubMed: 8759521)
    doi:10.1006/exer.1996.0063
    http://dx.doi.org/10.1006/exer.1996.0063

    38. Crawford DR, Wang Y, Schools GP, Kochheiser J, Davies KJ. Down-regulation of mammalian mitochondrial RNAs during oxidative stress. Free Radic Biol Med , 22 (3) : 551-59 (1997). (PubMed: 8981048 )
    doi:10.1016/S0891-5849%2896%2900380-2
    http://dx.doi.org/10.1016/S0891-5849%2896%2900380-2

    39. Zheng M, Aslund F, Storz G. Activation of the OxyR transcription factor by reversible disulfide bond formation. Science., 279 (5357): 1718-1721 (1998). (PubMed: 9497290)
    doi:10.1126/science.279.5357.1718
    http://dx.doi.org/10.1126/science.279.5357.1718

    40. Sundaresan M, Yu Z-X, Ferrans VJ, Irani K, Finkel T. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science. ,270 (5234):296-299 (1995). (PubMed: 7569979)
    doi:10.1126/science.270.5234.296
    http://dx.doi.org/10.1126/science.270.5234.296

    41. Sulciner DJ, Irani K, Yu Z-X, Ferrans VJ, Goldschmidt-Clermont P, Finkel T. racl regulates a cytokine-stimulated, redox-dependent pathway necessary for NFκB activation. Mol Cell Biol. ,16: 7115-7121 (1996). (PMID: 8943367), PMC231715

    42. Meyer M, Schreck R, Baeuerle PA. H2O2 and antioxidants have opposite effects on activation of NF-κB and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J. , 12: 2005-2015 (1993). (PubMed: 8491191) PMC413423

    43. Storz G, Polla BS. Transcriptional regulators of oxidative stress-inducible genes in prokaryotes and eukaryotes. In: U Feige, RI Morimoto, I Yahara, B Polla, eds. Stress-Inducible Cellular Responses. Basel, Switzerland: Birkhauser Verlag, 239-254 (1996).

    44. Blackburn EH. Structure and function of telomeres. Nature , 350: 569-73 (1991). (PubMed: 1708110)
    doi:10.1038/350569a0
    http://dx.doi.org/10.1038/350569a0

    45. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J., 14 (17): 4240-8 (1995). (PubMed: 7556065)

    46. Rowley PT. Telomerase: Putting an end to DNA. Cancer Invest., 16 (3): 170-4 (1998). (PubMed: 9541631)
    doi:10.3109/07357909809050032
    http://dx.doi.org/10.3109/07357909809050032

    47. Egan CA, Savre-Train I, Shay JW, Wilson SE, Bourne WM. Analysis of telomere lengths in human corneal endothelial cells from donors of different ages. Invest Ophthalmol Vis Sci , 39: 648-53 (1998). (PubMed: 9501879)

    48. van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end to end fusions. Cell , 92: 401-13 (1998). (PubMed: 9476899)
    doi:10.1016/S0092-8674%2800%2980932-0
    http://dx.doi.org/10.1016/S0092-8674%2800%2980932-0

    49. Greider CW. Telomere length regulation. Annu Rev Biochem. , 65:337-65 (1996). (PubMed: 8811183)
    doi:10.1146/annurev.bi.65.070196.002005
    http://dx.doi.org/10.1146/annurev.bi.65.070196.002005

    50.Collins K. Mammalian telomeres and telomerase. Curr Opin Cell Biol., Jun;12 (3):378-83 (2000). (PubMed: 10801465)
    doi:10.1016/S0955-0674%2800%2900103-4
    http://dx.doi.org/10.1016/S0955-0674%2800%2900103-4

    51. Feng J, Funk WD,Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J, Le S, West MD, Harley CB, Andrews WH, Greiolen CW, Villeponteau B. The RNA component of human telomerase. Science. ,Sep 1;269 (5228):1236-41 (1995). (PubMed: 7544491)
    doi:10.1126/science.7544491
    http://dx.doi.org/10.1126/science.7544491

    52.Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR. Telomerase catalytic subunit homologs from fission yeast and human. Science. , Aug 15;277 (5328):955-9. Comment in: Science. 1997 Aug 15;277 (5328):911-2 (1997). (PubMed: 9252327)
    doi:10.1126/science.277.5328.955
    http://dx.doi.org/10.1126/science.277.5328.955

    53. Axelrod N. Of telomeres and tumors. Nat Med , 2: 158-59 (1996). (PubMed: 8574955)
    doi:10.1038/nm0296-158
    http://dx.doi.org/10.1038/nm0296-158

    54. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P,Caddle SD,Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. , Aug 22;90 (4):785-95 (1997). (PubMed: 9288757)
    doi:10.1016/S0092-8674%2800%2980538-3
    http://dx.doi.org/10.1016/S0092-8674%2800%2980538-3

    55. Klingelhutz AJ. The roles of telomeres and telomerase in cellular immortalization and the development of cancer. Anticancer Res. , Nov-Dec;19 (6A):4823-30 (1999). (PubMed: 10697595 )

    56. Shay JW, Wright WE. Hallmarks of telomeres in ageing research. J Pathol. , Jan;211 (2):114-23 (2007). (PubMed: 17200948)
    doi:10.1002/path.2090
    http://dx.doi.org/10.1002/path.2090

    57. Meyerson M. Role of telomerase in normal and cancer cells. J Clin Oncol. , Jul;18 (13):2626-34 (2000). (PubMed:10893296)

    58. Ahmed S, Passos JF, Birket MJ, Beckmann T, Brings S, Peters H, Birch-Machin MA, von Zglinicki T, Saretzki G. Telomerase does not counteract telomere shortening but protects mitochondrial function under oxidative stress. J Cell Sci. , Apr 1;121 (Pt 7):1046-53. Epub 2008 Mar 11 (2008). (PubMed: 18334557)
    doi:10.1242/jcs.019372
    http://dx.doi.org/10.1242/jcs.019372

    59. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. Extension of life-span by introduction of telomerase into normal human cells. Science , 279: 349-352 (1998). (PubMed: 9454332)
    doi:10.1126/science.279.5349.349
    http://dx.doi.org/10.1126/science.279.5349.349

    60. Fu W, Killen M, Culmsee C, Dhar S, Pandita TK, Mattson MP. The catalytic subunit of telomerase is expressed in developing brain neurons and serves a cell survival-promoting function. J Mol Neurosci. , Feb-Apr;14 (1-2):3-15 (2000). (PubMed: 10854032)
    doi:10.1385/JMN%3A14%3A1-2%3A003
    http://dx.doi.org/10.1385/JMN%3A14%3A1-2%3A003

    61. Colitz CM, Davidson MG, McGAHAN MC. Telomerase activity in lens epithelial cells of normal and cataractous lenses. Exp Eye Res. , Dec;69 (6):641-9 (1999). (PubMed: 10620393 )
    doi:10.1006/exer.1999.0739
    http://dx.doi.org/10.1006/exer.1999.0739

    62. Pendergrass WR, Penn PE, Li J, Wolf NS. Age-related telomere shortening occurs in lens epithelium from old rats and is slowed by caloric restriction. Exp Eye Res. , Aug;73 (2):221-8 (2001). (PubMed: 11446772)
    doi:10.1006/exer.2001.1033
    http://dx.doi.org/10.1006/exer.2001.1033

    63. Huang XQ, Wang J, Liu JP, Feng H, Liu WB, Yan Q, Liu Y, Sun SM, Deng M, Gong L, Liu Y, Li DW. hTERT extends proliferative lifespan and prevents oxidative stress-induced apoptosis in human lens epithelial cells. Invest Ophthalmol Vis Sci. , Jul;46 (7):2503-13 (2005). (PubMed: 15980242)
    doi:10.1167/iovs.05-0154
    http://dx.doi.org/10.1167/iovs.05-0154

    64. del Bufalo D, Rizzo A, Trisciuoglio D, Cardinali G, Torrisi MR, Zangemeister-Wittke U, Biroccio A. Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function. Cell Death Differ. , 12: 1429-1438 (2005). (PubMed: 15920535)
    doi:10.1038/sj.cdd.4401670
    http://dx.doi.org/10.1038/sj.cdd.4401670

    65. Kang HJ, Choi YS, Hong SB, Kim KW, Woo RS, Won SJ, Kim EJ, Jeon HK, Jo SY, Kim TK, Bachoo R, Reynolds IJ, Gwag BJ, Lee HW. Ectopic expression of the catalytic subunit of telomerase protects against brain injury resulting from ischemia and NMDA-induced neurotoxicity. J Neurosci. , Feb 11;24 (6):1280-7 (2004). (PubMed: 14960598)
    doi:10.1523/JNEUROSCI.4082-03.2004
    http://dx.doi.org/10.1523/JNEUROSCI.4082-03.2004

    66. Ludwig A, Saretzki G, Holm PS, Tiemann F, Lorenz M, Emrich T, Harley CB, von Zglinicki T. Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res. , Apr 1;61 (7):3053-61 (2001). (PubMed: 11306487)

    67. Oh H, Taffet GE, Youker KA, Entman ML, Overbeek PA, Michael LH, Schneider MD.Telomerase reverse transcriptase promotes cardiac muscle cell proliferation, hypertrophy, and survival. Proc Natl Acad Sci U S A. , Aug 28;98 (18):10308-13. Epub 2001 Aug 21 (2001). (PubMed: 11517337)
    doi:10.1073/pnas.191169098
    http://dx.doi.org/10.1073/pnas.191169098

    68. Zhang P, Chan SL, Fu W, Mendoza M, Mattson MP. TERT suppresses apoptotis at a premitochondrial step by a mechanism requiring reverse transcriptase activity and 14-3-3 protein-binding ability. FASEB J. , Apr;17 (6):767-9. Epub 2003 Feb 19 (2003). (PubMed: 12594176)
    doi:10.1096/fj.02-0603fje
    http://dx.doi.org/10.1096/fj.02-0603fje

    69. Kondo Y, Kondo S, Tanaka Y, Haqqi T, Barna BP, Cowell JK. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Oncogene. , Apr 30;16 (17):2243-8 (1998). (PubMed: 9619833)
    doi:10.1038/sj.onc.1201754
    http://dx.doi.org/10.1038/sj.onc.1201754

    70. Sharma GG, Gupta A, Wang H, Scherthan H, Dhar S, Gandhi V, Iliakis G, Shay JW, Young CS, Pandita TK. hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene. , Jan 9;22 (1):131-46 (2003). (PubMed: 12527915)
    doi:10.1038/sj.onc.1206063
    http://dx.doi.org/10.1038/sj.onc.1206063

    71. Massard C, Zermati Y, Pauleau AL, Larochette N, Métivier D, Sabatier L, Kroemer G, Soria JC. hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway. Oncogene. , Aug 3;25 (33):4505-14. Epub 2006 Apr 17 (2006). (PubMed: 16619047)
    doi:10.1038/sj.onc.1209487
    http://dx.doi.org/10.1038/sj.onc.1209487

    72. Zhu H, Fu W, Mattson MP. The catalytic subunit of telomerase protects neurons against amyloid beta-peptide-induced apoptosis. J Neurochem. 2000 Jul;75 (1):117-24. (PubMed: 10854254)
    doi:10.1046/j.1471-4159.2000.0750117.x
    http://dx.doi.org/10.1046/j.1471-4159.2000.0750117.x

    73. Clayton RM, Cuthbert J, Duffy J, Seth J, Phillips CI, Bartholomew RS, Reid JM. Some risk factors associated with cataract in S.E. Scotland: a pilot study. Trans Ophthalmol Soc U K. ,102 Pt 3:331-6 (1982). (PubMed: 6964276)

    74. Costagliola C, Iuliano G, Menzione M, Nesti A, Simonelli F, Rinaldi E. Systemic human diseases as oxidative risk factors in cataractogenesis. I. Diabetes. Ophthalmic Res. ,20 (5):308-16 (1988). (PubMed: 3186203)

    75. Costagliola C, Iuliano G, Menzione M, Simonelli F, Tortori A, Masturzi B, di Benedetto A, Rinaldi E. Systemic human diseases as oxidative risk factors in cataractogenesis. II. Chronic renal failure. Exp Eye Res. , Dec;51 (6):631-5 (1990). (PubMed: 2265673)
    doi:10.1016/0014-4835%2890%2990046-W
    http://dx.doi.org/10.1016/0014-4835%2890%2990046-W

    76. Simonelli F, Nesti A, Pensa M, Romano L, Savastano S, Rinaldi E, Auricchio G. Lipid peroxidation and human cataractogenesis in diabetes and severe myopia. Exp Eye Res. , Aug;49 (2):181-7 (1989). (PubMed: 2767166 )
    doi:10.1016/0014-4835%2889%2990088-2
    http://dx.doi.org/10.1016/0014-4835%2889%2990088-2

    77. Bhuyan KC, Master RW, Coles RS, Bhuyan DK. Molecular mechanisms of cataractogenesis: IV. Evidence of phospholipid . malondialdehyde adduct in human senile cataract. Mech Ageing Dev. , May;34 (3):289-96 (1986). (PubMed: 3724254)
    doi:10.1016/0047-6374%2886%2990080-1
    http://dx.doi.org/10.1016/0047-6374%2886%2990080-1

    78. Borchman D, Yappert MC, Rubini RQ, Paterson CA. Distribution of phospholipid-malondialdehyde-adduct in the human lens. Curr Eye Res. , Sep;8 (9):939-46 (1989). (PubMed: 2791635)

    79. Bhuyan KC, Bhuyan DK, Podos SM. Lipid peroxidation in cataract of the human. Life Sci. , Apr 21;38 (16):1463-71 (1986). (PubMed: 3702587 )
    doi:10.1016/0024-3205%2886%2990559-X
    http://dx.doi.org/10.1016/0024-3205%2886%2990559-X

    80. Bhuyan KC, Bhuyan DK, Podos SM. Free radical enhancer xenobiotic is an inducer of cataract in rabbit. Free Radic Res Commun. ,12-13 Pt 2:609-20 (1991). (PubMed: 1648013 )
    doi:10.3109/10715769109145837
    http://dx.doi.org/10.3109/10715769109145837

    81. Mibu H, Nagata M, Hikida M. A study on lipid peroxide-induced lens damage in vitro. Exp Eye Res. , Jan;58 (1):85-90 (1994). (PubMed: 7908884)
    doi:10.1006/exer.1994.1197
    http://dx.doi.org/10.1006/exer.1994.1197

    82. Srivastava SK, Awasthi S, Wang L, Bhatnagar A, Awasthi YC, Ansari NH. Attenuation of 4-hydroxynonenal-induced cataractogenesis in rat lens by butylated hydroxytoluene. Curr Eye Res. , Jul;15 (7):749-54 (1996).
    doi:10.3109/02713689609003458
    http://dx.doi.org/10.3109/02713689609003458

    83. Nishigori H, Lee JW, Yamauchi Y, Iwatsuru M. The alteration of lipid peroxide in glucocorticoid-induced cataract of developing chick embryos and the effect of ascorbic acid. Curr Eye Res. , Jan;5 (1):37-40 (1986). (PubMed: 3956234 )
    doi:10.3109/02713688608995163
    http://dx.doi.org/10.3109/02713688608995163

    84.Yagi K, Komura S, Ihara N, Abe H, Konishi H, Arichi S. Serum lipid peroxide levels in rats with inherited cataracts. J Appl Biochem. , Jun;7 (3):202-6 (1985). (PubMed: 4055555)

    85. Zigler JS Jr, Bodaness RS, Gery I, Kinoshita JH. Effects of lipid peroxidation products on the rat lens in organ culture: a possible mechanism of cataract initiation in retinal degenerative disease. Arch Biochem Biophys. , Aug; 225 (1): 149-56 (1983). (PubMed: 6614915 )
    doi:10.1016/0003-9861%2883%2990018-8
    http://dx.doi.org/10.1016/0003-9861%2883%2990018-8

    86. Zigler JS Jr, Gery I, Kessler D, Kinoshita JH. Macrophage mediated damage to rat lenses in culture: a possible model for uveitis-associated cataract. Invest Ophthalmol Vis Sci. , May;24 (5):651-4 (1983). (PubMed: 6841016 )

    87. Goosey JD, Tuan WM, Garcia CA. A lipid peroxidative mechanism for posterior subcapsular cataract formation in the rabbit: a possible model for cataract formation in tapetoretinal diseases. Invest Ophthalmol Vis Sci. , May;25 (5):608-12 (1984). (PubMed: 6232239)

    88. Zigler JS Jr, Hess HH. Cataracts in the Royal College of Surgeons rat: evidence for initiation by lipid peroxidation products. Exp Eye Res. , Jul;41 (1):67-76 (1985). (PubMed: 4029287)
    doi:10.1016/0014-4835%2885%2990095-8
    http://dx.doi.org/10.1016/0014-4835%2885%2990095-8

    89. Babizhayev MA, Dainyak BA, Maxina AH. ESR spin label and ultrastructural monitoring of protein-lipid interactions in the lens fiber-cell plasma membranes in relation to human ageing and cataractogenesis. Mech Ageing Dev. Jun;64 (1-2):133-47 (1992). (PubMed: 1321312 )
    doi:10.1016/0047-6374%2892%2990102-J
    http://dx.doi.org/10.1016/0047-6374%2892%2990102-J

    90. Borchman D, Lamba OP, Salmassi S, Lou M, Yappert MC. The dual effect of oxidation on lipid bilayer structure. Lipids. , Apr; 27 (4):261-5 (1992). (PubMed: 1518382 )
    doi:10.1007/BF02536472
    http://dx.doi.org/10.1007/BF02536472

    91. Borchman D, Lamba OP, Yappert MC. Structural characterization of lipid membranes from clear and cataractous human lenses. Exp Eye Res. , Aug;57 (2):199-208 (1993). (PubMed: 8405186 )
    doi:10.1006/exer.1993.1115
    http://dx.doi.org/10.1006/exer.1993.1115

    92. Huang L, Estrada R, Yappert MC, Borchman D. Oxidation-induced changes in human lens epithelial cells. 1. Phospholipids. Free Radic Biol Med. , Nov 1;41 (9):1425-32. Epub 2006 Aug 4 (2006). (PubMed: 17023269 )
    doi:10.1016/j.freeradbiomed.2006.07.022
    http://dx.doi.org/10.1016/j.freeradbiomed.2006.07.022

    93. Huang L, Tang D, Yappert MC, Borchman D. Oxidation-induced changes in human lens epithelial cells 2. Mitochondria and the generation of reactive oxygen species. Free Radic Biol Med. , Sep 15;41 (6):926-36. Epub 2006 May 26 (2006). (PubMed: 16934675)
    doi:10.1016/j.freeradbiomed.2006.05.023
    http://dx.doi.org/10.1016/j.freeradbiomed.2006.05.023

    94. Borchman D, Paterson CA, Delamere NA. Oxidative inhibition of Ca2+-ATPase in the rabbit lens. Invest Ophthalmol Vis Sci. , Jul;30 (7):1633-7 (1989). (PubMed: 2545647)

    95. Kagan VE Lipid Peroxidation in Biomembranes, p.181. CRC Press, Boca Raton, FL (1988).

    96. Park JW, Floyd RA. Lipid peroxidation products mediate the formation of 8-hydroxydeoxyguanosine in DNA. Free Radic Biol Med. ,12 (4):245-50 (1992). (PubMed: 1315708 )
    doi:10.1016/0891-5849%2892%2990111-S
    http://dx.doi.org/10.1016/0891-5849%2892%2990111-S

    97. Babizhayev MA, Deyev AI, Linberg LF. Lipid peroxidation as a possible cause of cataract. Mech Ageing Dev. , Jul;44 (1):69-89 (1988). (PubMed: 3205065)
    doi:10.1016/0047-6374%2888%2990080-2
    http://dx.doi.org/10.1016/0047-6374%2888%2990080-2

    98. Babizhayev MA. Lipid fluorophores of the human crystalline lens with cataract. Graefes Arch Clin Exp Ophthalmol. 227 (4): 384-91 (1989). (PubMed: 2777108)
    doi:10.1007/BF02169418
    http://dx.doi.org/10.1007/BF02169418

    99. Babizhayev MA. Antioxidant activity of L-carnosine, a natural histidine-containing dipeptide in crystalline lens. Biochim Biophys Acta. , Aug 22; 1004 (3): 363-71 (1989). (PubMed: 2758030)

    100. Kikugawa K, Kato T, Beppu M, Hayasaka A. Development of fluorescence and cross-links in eye lens crystallin by interaction with lipid peroxy radicals. Biochim Biophys Acta. , Feb 22; 1096 (2):108-14 (1991). (PubMed: 2001425)
    doi:10.1016/0925-4439%2891%2990047-D
    http://dx.doi.org/10.1016/0925-4439%2891%2990047-D

    101. Ferrer JV, Gascó E, Sastre J, Pallardó FV, Asensi M, Viña J. Age-related changes in glutathione synthesis in the eye lens. Biochem J. , Jul 15;269 (2):531-4 (1990). (PubMed: 2386490 )

    102. Shin AH, Oh CJ, Park JW. Glycation-induced inactivation of antioxidant enzymes and modulation of cellular redox status in lens cells. : Arch Pharm Res. , Jul;29 (7):577-81 (2006). (PubMed: 16903078)
    doi:10.1007/BF02969268
    http://dx.doi.org/10.1007/BF02969268

    103. Goosey JD, Zigler JS Jr, Kinoshita JH. Cross-linking of lens crystallins in a photodynamic system: a process mediated by singlet oxygen. Science. , Jun 13;208 (4449):1278-80 (1980). (PubMed: 7375939)
    doi:10.1126/science.7375939
    http://dx.doi.org/10.1126/science.7375939

    104. Egorov SIu, Babizhaev MA, Krasnovskiĭ AA Jr, Shvedova AA. (Photosensitized generation of singlet molecular oxygen by endogenous substances of the eye lens). Biofizika. , Jan-Feb;32 (1):169-71 (1987). (PubMed: 3814638 )

    105. Bhuyan KC, Bhuyan DK. Regulation of hydrogen peroxide in eye humors. Effect of 3-amino-1H-1,2,4-triazole on catalase and glutathione peroxidase of rabbit eye. Biochim Biophys Acta. , May 26;497 (3):641-51 (1977). (PubMed: 889879 )
    doi:10.1016/0304-4165%2877%2990284-7
    http://dx.doi.org/10.1016/0304-4165%2877%2990284-7

    106. Bhuyan KC, Bhuyan DK. Superoxide dismutase of the eye: relative functions of superoxide dismutase and catalase in protecting the ocular lens from oxidative damage. Biochim Biophys Acta. , Aug 3;542 (1):28-38 (1978). (PubMed: 208649)
    doi:10.1016/0304-4165%2878%2990229-5
    http://dx.doi.org/10.1016/0304-4165%2878%2990229-5

    107. Bhuyan KC, Bhuyan DK. Molecular mechanism of cataractogenesis: III. Toxic metabolites of oxygen as initiators of lipid peroxidation and cataract. Curr Eye Res. Jan;3 (1):67-81 (1984). (PubMed: 6317286 )
    doi:10.3109/02713688408997188
    http://dx.doi.org/10.3109/02713688408997188

    108. Babizhaev MA, Deev AI, Vladimirov IuA, Deeva IB. (Decomposition of H2O2 by human cataractous lenses) Biull Eksp Biol Med. Aug;102 (8):158-60 (1986). (PubMed: 3742026 )
    doi:10.1007/BF00836191
    http://dx.doi.org/10.1007/BF00836191

    109. Fecondo JV, Augusteyn RC. Superoxide dismutase, catalase and glutathione peroxidase in the human cataractous lens. Exp Eye Res. , Jan;36 (1):15-23 (1983). (PubMed: 6825728)
    doi:10.1016/0014-4835%2883%2990085-4
    http://dx.doi.org/10.1016/0014-4835%2883%2990085-4

    110. Rao GN, Sadasivudu B, Cotlier E. Studies on glutathione S-transferase, glutathione peroxidase and glutathione reductase in human normal and cataractous lenses. Ophthalmic Res. ,15 (4):173-9 (1983). (PubMed: 6138744 )
    doi:10.1159/000265254
    http://dx.doi.org/10.1159/000265254

    111. Spector A, Garner WH. Hydrogen peroxide and human cataract. Exp Eye Res. , Dec;33 (6):673-81 (1981). (PubMed: 7318962 )
    doi:10.1016/S0014-4835%2881%2980107-8
    http://dx.doi.org/10.1016/S0014-4835%2881%2980107-8

    112. PIRIE A. GLUTATHIONE PEROXIDASE IN LENS AND A SOURCE OF HYDROGEN PEROXIDE IN AQUEOUS HUMOUR. Biochem J. , Jul;96:244-53 (1965). (PubMed: 14343138 )

    113. PIRIE A. A LIGHT-CALALYSED REACTION IN THE AQUEOUS HUMOR OF THE EYE. Nature. , Jan 30;205: 500-1 (1965). (PubMed: 14265299)
    doi:10.1038/205500a0
    http://dx.doi.org/10.1038/205500a0

    114. Dwivedi RS, Pratap VB. Alteration in glutathione metabolism during cataract progression. Ophthalmic Res. ,19 (1):41-4 (1987). (PubMed: 3601355 )
    doi:10.1159/000265469
    http://dx.doi.org/10.1159/000265469

    115. Scharf J, Dovrat A, Gershon D. Defective superoxide-dismutase molecules accumulate with age in human lenses. Graefes Arch Clin Exp Ophthalmol. ,225 (2):133-6 (1987). (PubMed: 3556330)
    doi:10.1007/BF02160345
    http://dx.doi.org/10.1007/BF02160345

    116. Reddy VN. Glutathione and its function in the lens--an overview. Exp Eye Res. , Jun;50 (6):771-8 (1990). (PubMed: 2197112)
    doi:10.1016/0014-4835%2890%2990127-G
    http://dx.doi.org/10.1016/0014-4835%2890%2990127-G

    117. Rathbun WB. In Glutathione: Chemical, Biochemical, and Medical Aspects, Part B (Dolphin D, Poulson R and Avramovic O, ed) pp.467-510, Wiley, New York (1989).

    118. Harding JJ. Free and protein-bound glutathione in normal and cataractous human lenses. Biochem J. , May;117 (5): 957-60 (1970). (PubMed: 5451916)

    119. Varma SD, Kumar S, Richards RD. Light-induced damage to ocular lens cation pump: prevention by vitamin C. Proc Natl Acad Sci U S A. , Jul;76 (7):3504-6 (1979). (PubMed: 291017)
    doi:10.1073/pnas.76.7.3504
    http://dx.doi.org/10.1073/pnas.76.7.3504

    120. Wolff SP, Wang GM, Spector A. Pro-oxidant activation of ocular reductants. 1. Copper and riboflavin stimulate ascorbate oxidation causing lens epithelial cytotoxicity in vitro. Exp Eye Res. , Dec;45 (6):777-89 (1987). (PubMed: 2828093 )
    doi:10.1016/S0014-4835%2887%2980095-7
    http://dx.doi.org/10.1016/S0014-4835%2887%2980095-7

    121. Saez G, Thornalley PJ, Hill HA, Hems R, Bannister JV. The production of free radicals during the autoxidation of cysteine and their effect on isolated rat hepatocytes. Biochim Biophys Acta. , Oct 28;719 (1):24-31 (1982). (PubMed: 6293586)
    doi:10.1016/0304-4165%2882%2990302-6
    http://dx.doi.org/10.1016/0304-4165%2882%2990302-6

    122. Nath R, Srivastava SK, Singh K. Accumulation of copper and inhibition of lactate dehydrogenase activity in human senile cataractous lens. Indian J Exp Biol. , Jan;7 (1):25-6 (1969). (PubMed: 5771164 )

    123. Gerhard JP. (Study of copper in the aqueous humor) Doc Ophthalmol., 20:104-10 (1966). (PubMed: 5982252)

    124. HARMAN D. THE FREE RADICAL THEORY OF AGING: EFFECT OF AGE ON SERUM COPPER LEVELS. J Gerontol. , Apr;20:151-3 (1965). (PubMed: 14284786 )

    125. Noto R, Alicata R, Sfogliano L, Neri S, Bifarella M. A study of cupremia in a group of elderly diabetics. Acta Diabetol Lat. , Jan-Mar;20 (1):81-5 (1983). (PubMed: 6858545)
    doi:10.1007/BF02629133
    http://dx.doi.org/10.1007/BF02629133

    126. Babizhayev MA, Guiotto A, Kasus-Jacobi A. N-Acetylcarnosine and histidyl-hydrazide are potent agents for multitargeted ophthalmic therapy of senile cataracts and diabetic ocular complications. J. Drug Target. Jan;17 (1):36-63 (2009). (PubMed: 19037813)
    doi:10.1080/10611860802438736
    http://dx.doi.org/10.1080/10611860802438736

    127. Babizhayev MA, Kasus-Jacobi A. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases. Curr. Clin. Pharmacol. Jan;4 (1):4-37 (2009). (PubMed: 19149498)
    doi:10.2174/157488409787236074
    http://dx.doi.org/10.2174/157488409787236074

    128. Babizhayev MA, Micans P, Guiotto A, Kasus-Jacobi A. N-Acetylcarnosine Lubricant Eyedrops Possess All-In-One Universal Antioxidant Protective Effects of L-Carnosine in Aqueous and Lipid Membrane Environments, Aldehyde Scavenging, and Transglycation Activities Inherent to Cataracts: A Clinical Study of the New Vision-Saving Drug N-Acetylcarnosine Eyedrop Therapy in a Database Population of Over 50,500 Patients. Am J Ther. Nov-Dec;16 (6):517-533 (2009). (PubMed: 19487926)
    doi:10.1097/MJT.0b013e318195e327
    http://dx.doi.org/10.1097/MJT.0b013e318195e327

    129. Babizhayev MA, Burke L, Micans P, Richer SP. N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision: Glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50,000-patient population. Clin Interv Aging. 4 (1):31-50 (2009). Epub 2009 May 14 . (PubMed: 19503764)

    130. Babizhayev MA. Current Ocular Drug Delivery Challenges for N-acetylcarnosine : Novel Patented Routes and Modes of Delivery, Design for Enhancement of Therapeutic Activity and Drug Delivery Relationships. Recent Pat Drug Deliv Formul. , 3 (3): 229-265 (2009). (PubMed: 19534670)
    doi:10.2174/187221109789105621
    http://dx.doi.org/10.2174/187221109789105621

    131. Shawi M, Autexier C. Telomerase, senescence and ageing. Mech Ageing Dev. , Jan-Feb;129 (1-2):3-10. Epub 2007 Dec 14 (2008). (PubMed: 18215413 )
    doi:10.1016/j.mad.2007.11.007
    http://dx.doi.org/10.1016/j.mad.2007.11.007

    132. Chen Q, Ames BN. Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast F65 cells. Proc Natl Acad Sci U S A. , May 10;91 (10): 4130-4 (1994). (PubMed: 8183882)
    doi:10.1073/pnas.91.10.4130
    http://dx.doi.org/10.1073/pnas.91.10.4130

    133. von Zglinicki T, Saretzki G, Döcke W, Lotze C. Mild hyperoxia shortens telomeres and inhibits proliferation of fibroblasts: a model for senescence? Exp Cell Res., Sep; 220 (1):186-93 (1995). (PubMed: 7664835)
    doi:10.1006/excr.1995.1305
    http://dx.doi.org/10.1006/excr.1995.1305

    134.Unterluggauer H, Hampel B, Zwerschke W, Jansen-Dürr P. Senescence-associated cell death of human endothelial cells: the role of oxidative stress. Exp Gerontol. , Oct;38 (10):1149-60 (2003). (PubMed: 14580868 )
    doi:10.1016/j.exger.2003.08.007
    http://dx.doi.org/10.1016/j.exger.2003.08.007

    135. Kurz DJ, Decary S, Hong Y, Trivier E, Akhmedov A, Erusalimsky JD. Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells. J Cell Sci. , May 1;117 (Pt 11):2417-26 (2004). (PubMed: 15126641)
    doi:10.1242/jcs.01097
    http://dx.doi.org/10.1242/jcs.01097

    136.Colavitti R, Finkel T. Reactive oxygen species as mediators of cellular senescence. IUBMB Life. , Apr-May;57 (4-5):277-81 (2005). (PubMed: 16036611)
    doi:10.1080/15216540500091890
    http://dx.doi.org/10.1080/15216540500091890

    137. Miquel J. An integrated theory of aging as the result of mitochondrial-DNA mutation in differentiated cells. Arch Gerontol Geriatr. ,Mar-Jun;12 (2-3):99-117 (1991). (PubMed: 15374442)
    doi:10.1016/0167-4943%2891%2990022-I
    http://dx.doi.org/10.1016/0167-4943%2891%2990022-I

    138. Hutter E, Renner K, Pfister G, Stöckl P, Jansen-Dürr P, Gnaiger E. Senescence-associated changes in respiration and oxidative phosphorylation in primary human fibroblasts. Biochem J. , Jun 15;380 (Pt 3):919-28 (2004). (PubMed: 15018610)
    doi:10.1042/BJ20040095
    http://dx.doi.org/10.1042/BJ20040095

    139. Stöckl P, Zankl C, Hütter E, Unterluggauer H, Laun P, Heeren G, Bogengruber E, Herndler-Brandstetter D, Breitenbach M, Jansen-Dürr P. Partial uncoupling of oxidative phosphorylation induces premature senescence in human fibroblasts and yeast mother cells. Free Radic Biol Med. ,Sep 15;43 (6):947-58. (2007) Epub 2007 Jun 13. (PubMed: 17697939)
    doi:10.1016/j.freeradbiomed.2007.06.005
    http://dx.doi.org/10.1016/j.freeradbiomed.2007.06.005

    140. Passos JF, Saretzki G, Ahmed S, Nelson G, Richter T, Peters H, Wappler I, Birket MJ, Harold G, Schaeuble K, Birch-Machin MA, Kirkwood TB, von Zglinicki T. Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence. PLoS Biol. , May;5 (5):e110 (2007). (PubMed: 17472436)
    doi:10.1371/journal.pbio.0050110
    http://dx.doi.org/10.1371/journal.pbio.0050110

    141.von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci.,Jul;27 (7):339-44 (2002). (PubMed: 12114022 )
    doi:10.1016/S0968-0004%2802%2902110-2
    http://dx.doi.org/10.1016/S0968-0004%2802%2902110-2

    142. Serra V, von Zglinicki T, Lorenz M, Saretzki G. Extracellular superoxide dismutase is a major antioxidant in human fibroblasts and slows telomere shortening. J Biol Chem. Feb 28;278 (9):6824-30 (2003). Epub 2002 Dec 9. (PubMed: 12475988)
    doi:10.1074/jbc.M207939200
    http://dx.doi.org/10.1074/jbc.M207939200

    143.Saretzki G, Von Zglinicki T. Replicative aging, telomeres, and oxidative stress. Ann N Y Acad Sci. ,Apr;959:24-9 (2002). (PubMed: 11976182)

    144. von Zglinicki T. Role of oxidative stress in telomere length regulation and replicative senescence. Ann N Y Acad Sci. , Jun;908:99-110 (2000). (PubMed: 10911951)

    145. Petersen S, Saretzki G, von Zglinicki T. Preferential accumulation of single-stranded regions in telomeres of human fibroblasts. Exp Cell Res., Feb 25;239 (1):152-60 (1998). (PubMed: 9511733 )
    doi:10.1006/excr.1997.3893
    http://dx.doi.org/10.1006/excr.1997.3893

    146. Sitte N, Saretzki G, von Zglinicki T. Accelerated telomere shortening in fibroblasts after extended periods of confluency. Free Radic Biol Med. , Apr;24 (6):885-93 (1998). (PubMed: 9607597 )
    doi:10.1016/S0891-5849%2897%2900363-8
    http://dx.doi.org/10.1016/S0891-5849%2897%2900363-8

    147. Paterson CA, Delamere NA . The Lens. In: Hart, W. M. (ed.) Adler's Physiology of the Eye. Mosby Year Book, St. Louis, pp. 348-90 (1992).

    148. Kuszak JR. A re-examination of primate lens epithelial cell size, density and structure as a function of development, growth and age. Nova Acta Leopoldina , 75: 45-66 (1997).

    149. Harding CV, Reddan JR, Unakar NJ, Bagchi M. The control of cell division in the ocular lens. Int Rev Cytol. 1971;31:215-300 (1971). (PubMed: 4945052 )
    doi:10.1016/S0074-7696%2808%2960060-1
    http://dx.doi.org/10.1016/S0074-7696%2808%2960060-1

    150. McAvoy JW, McDonald J. Proliferation of lens epithelial explants in culture increases with age of donor rat. Curr Eye Res. , Sep;3 (9):1151-3 (1984). (PubMed: 6488865)
    doi:10.3109/02713688409000815
    http://dx.doi.org/10.3109/02713688409000815

    151. Bodnar AG, Kim NW, Effros RB, Chiu CP. Mechanism of telomerase induction during T cell activation. Exp Cell Res. , Oct 10;228 (1):58-64 (1996). (PubMed: 8892971 )
    doi:10.1006/excr.1996.0299
    http://dx.doi.org/10.1006/excr.1996.0299

    152. Russo I, Silver AR, Cuthbert AP, Griffin DK, Trott DA, Newbold RF. A telomere-independent senescence mechanism is the sole barrier to Syrian hamster cell immortalization. Oncogene. , Dec 31;17 (26):3417-26 (1998). (PubMed: 10030665)
    doi:10.1038/sj.onc.1202261
    http://dx.doi.org/10.1038/sj.onc.1202261

    153. Ishikawa F. Regulation mechanisms of mammalian telomerase. A review. Biochemistry (Mosc). , Nov;62 (11):1332-7 (1997). (PubMed: 9467858 )

    154. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. Extension of life-span by introduction of telomerase into normal human cells. Science. , Jan 16;279 (5349):349-52 (1998). Comment in: Science., Jan 16;279 (5349):334-5 (1998). (PubMed: 9454332)
    doi:10.1126/science.279.5349.349
    http://dx.doi.org/10.1126/science.279.5349.349

    155. Kleiman NJ, Wang RR, Spector A. Ultraviolet light induced DNA damage and repair in bovine lens epithelial cells. Curr Eye Res. , Dec;9 (12):1185-93 (1990). (PubMed: 2091898)
    doi:10.3109/02713689009003475
    http://dx.doi.org/10.3109/02713689009003475

    156. Cristofalo VJ, Volker C, Francis MK, Tresini M. Age-dependent modifications of gene expression in human fibroblasts. Crit Rev Eukaryot Gene Expr. ,8 (1):43-80 (1998). (PubMed: 9673450 )

    157. Pendergrass WR, Penn PE, Li J, Wolf NS. Age-related telomere shortening occurs in lens epithelium from old rats and is slowed by caloric restriction. Exp Eye Res. , Aug;73 (2):221-8 (2001). (PubMed: 11446772)
    doi:10.1006/exer.2001.1033
    http://dx.doi.org/10.1006/exer.2001.1033

    158. Blackburn EH. Telomere states and cell fates. Nature , 408: 53-6 (2000). (PubMed: 11081503)
    doi:10.1038/35040500
    http://dx.doi.org/10.1038/35040500

    159. von Zglinicki T, Pilger R, Sitte N. Accumulation of single-strand breaks is the major cause of telomere shortening in human fibroblasts. Free Radic Biol Med. , Jan 1;28 (1):64-74 (2000). (PubMed: 10656292)
    doi:10.1016/S0891-5849%2899%2900207-5
    http://dx.doi.org/10.1016/S0891-5849%2899%2900207-5

    160. Nugent CI, Lundblad V. The telomerase reverse transcriptase: components and regulation. Genes Dev. , Apr 15;12 (8):1073-85 (1998). (PubMed: 9553037 )
    doi:10.1101/gad.12.8.1073
    http://dx.doi.org/10.1101/gad.12.8.1073

    161. Kleiman NJ, Spector A. DNA single strand breaks in human lens epithelial cells from patients with cataract. Curr Eye Res. , May;12 (5):423-31 (1993). (PubMed: 8344066)
    doi:10.3109/02713689309024624
    http://dx.doi.org/10.3109/02713689309024624

    162. Wang J, Feng H, Huang XQ, Xiang H, Mao YW, Liu JP, Yan Q, Liu WB, Liu Y, Deng M, Gong L, Sun S, Luo C, Liu SJ, Zhang XJ, Liu Y, Li DW. Human telomerase reverse transcriptase immortalizes bovine lens epithelial cells and suppresses differentiation through regulation of the ERK signaling pathway. J Biol Chem., Jun 17; 280 (24): 22776-87 (2005). Epub 2005 Apr 22. (PubMed: 15849192)
    doi:10.1074/jbc.M500032200
    http://dx.doi.org/10.1074/jbc.M500032200

    163. Xiang H, Wang J, Mao Y, Liu M, Reddy VN, Li DW. Human telomerase accelerates growth of lens epithelial cells through regulation of the genes mediating RB/E2F pathway. Oncogene. , May 23;21 (23):3784-91 (2002). (PubMed:12032846)
    doi:10.1038/sj.onc.1205455
    http://dx.doi.org/10.1038/sj.onc.1205455

    164. Huang XQ, Wang J, Liu JP, Feng H, Liu WB, Yan Q, Liu Y, Sun SM, Deng M, Gong L, Liu Y, Li DW. hTERT extends proliferative lifespan and prevents oxidative stress-induced apoptosis in human lens epithelial cells. Invest Ophthalmol Vis Sci. , Jul;46 (7):2503-13 (2005). (PubMed: 15980242 )
    doi:10.1167/iovs.05-0154
    http://dx.doi.org/10.1167/iovs.05-0154

    165. Babizhayev MA, Deyev AI, Yermakova VN, Davydova NG, Kurysheva NI, Doroshenko VS, Zhukotskii AV. Image analysis and glare sensitivity in human age-related cataracts. Clin Exp Optom. , May;86 (3):157-72 (2003). (PubMed: 12767250)
    doi:10.1111/j.1444-0938.2003.tb03098.x
    http://dx.doi.org/10.1111/j.1444-0938.2003.tb03098.x

    166. Babizhayev MA, Seguin M-C. Process of assessment of ocular disfunctions and implementation devices of this process. US Patent No. 6,007,203. Date of patent: December 28, 1999.

    167. Severin S.E. Problems concerned with the biological activity of naturally occurring imidazole compounds. Proceedings of Plen. Sess. Seventh International Biochemical Congress NY, pp.45-61 (1964).

    168. Boldyrev AA, Severin SE. The histidine-containing dipeptides, carnosine and anserine: distribution, properties and biological significance. Adv Enzyme Regul. , 30, 175-194 (1990). (PubMed: 2206021)
    doi:10.1016/0065-2571%2890%2990017-V
    http://dx.doi.org/10.1016/0065-2571%2890%2990017-V

    169. Lenney JF. Specificity and distribution of mammalian carnosinase. Biochim Biophys Acta. , Mar 11;429 (1):214-9 (1976). (PubMed: 1260030 )
    doi:10.1016/0005-2744%2876%2990044-9
    http://dx.doi.org/10.1016/0005-2744%2876%2990044-9

    170. Jackson MC, Kucera CM, Lenney JF. Purification and properties of human serum carnosinase. Clin Chim Acta. , Feb 15; 196 (2-3):193-205 (1991). (PubMed: 1903095)
    doi:10.1016/0009-8981%2891%2990073-L
    http://dx.doi.org/10.1016/0009-8981%2891%2990073-L

    171. Lenney JF. Separation and characterization of two carnosine-splitting cytosolic dipeptidases from hog kidney (carnosinase and non-specific dipeptidase). Biol Chem Hoppe Seyler. , May;371 (5):433-40 (1990). (PubMed: 2378680 )

    172. Kunze N, Kleinkauf H, Bauer K. Characterization of two carnosine-degrading enzymes from rat brain. Partial purification and characterization of a carnosinase and a beta-alanyl-arginine hydrolase. Eur J Biochem. , Nov 3;160 (3):605-13 (1986). (PubMed: 3780724)
    doi:10.1111/j.1432-1033.1986.tb10081.x
    http://dx.doi.org/10.1111/j.1432-1033.1986.tb10081.x

    173. Boldyrev AA, Dupin AM, Bunin AYa, Babizhayev MA, Severin SE. The antioxidative properties of carnosine, a natural histidine containing dipeptide. Biochem Int , 15: 1105-13 (1987). (PubMed: 3326603 )

    174. Aldini G, Facino RM, Beretta G, Carini M. Carnosine and related dipeptides as quenchers of reactive carbonyl species: from structural studies to therapeutic perspectives. Biofactors. , 24 (1-4):77-87 (2005). (PubMed: 16403966)
    doi:10.1002/biof.5520240109
    http://dx.doi.org/10.1002/biof.5520240109

    175. Aldini G, Orioli M, Carini M, Maffei Facino R. Profiling histidine-containing dipeptides in rat tissues by liquid chromatography/electrospray ionization tandem mass spectrometry. J Mass Spectrom. , Dec;39 (12):1417-28 (2004). (PubMed: 15578740)
    doi:10.1002/jms.696
    http://dx.doi.org/10.1002/jms.696

    176. Orioli M, Aldini G, Beretta G, Facino RM, Carini M. LC-ESI-MS/MS determination of 4-hydroxy-trans-2-nonenal Michael adducts with cysteine and histidine-containing peptides as early markers of oxidative stress in excitable tissues. J Chromatogr B Analyt Technol Biomed Life Sci. , Nov 15;827 (1):109-18 (2005). (PubMed: 15916929)
    doi:10.1016/j.jchromb.2005.04.025
    http://dx.doi.org/10.1016/j.jchromb.2005.04.025

    177. Reddy VP, Garrett MR, Perry G, Smith MA. Carnosine: a versatile antioxidant and antiglycating agent. Sci Aging Knowledge Environ. , May 4; 2005 (18):pe12 (2005). (PubMed: 15872311)
    doi:10.1126/sageke.2005.18.pe12
    http://dx.doi.org/10.1126/sageke.2005.18.pe12

    178. Rashid I, van Reyk DM, Davies MJ .Carnosine and its constituents inhibit glycation of low-density lipoproteins that promotes foam cell formation in vitro. FEBS Lett.,581 (5): 1067-70 (2007). (PubMed: 17316626)
    doi:10.1016/j.febslet.2007.01.082
    http://dx.doi.org/10.1016/j.febslet.2007.01.082

    179. Babizhayev, M.A.,Deyev,A.I.,Yermakova,V.N.,Semiletov,Yu.A.,Davydova,N.G.,Kurysheva,N.I., Zhukotskii, A.V.,Goldman, I.M.. N-Acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts. Peptides , 22: 979-994 (2001). (PubMed: 11390029)
    doi:10.1016/S0196-9781%2801%2900407-7
    http://dx.doi.org/10.1016/S0196-9781%2801%2900407-7

    180. Babizhayev, M.A., Deyev, A.I., Yermakova, V.N., Semiletov, Y.A., Davydova, N.G., Doroshenko, V.S., Zhukotskii, A.V., Goldman, I.M.. Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs in Research & Development. , 3 (2): 87-103 (2002). (PubMed: 12001824)
    doi:10.2165/00126839-200203020-00004
    http://dx.doi.org/10.2165/00126839-200203020-00004

    181. Babizhayev, M.A., Deyev, A.I., Yermakova, V.N., Remenschikov, V.V., Bours, J.. Revival of the lens transparency with N-acetylcarnosine. Current Drug Therapy , 1: 91-116 (2006).
    doi:10.2174/157488506775268425
    http://dx.doi.org/10.2174/157488506775268425

    182. Babizhayev, M.A., 2004. Method for topical treatment of eye disease and composition and device for said treatment. PCT Patent Application. International Publication Number WO 2004/028536 A1. International Publication Date: 8 April 2004.

    183. Babizhayev, M.A.. Ophthalmic pharmacology of N-acetylcarnosine lubricant eye drops . Journal of Pharmacology and Toxicology ,1 (3), 201-233 (2006).
    doi:10.3923/jpt.2006.201.233
    http://dx.doi.org/10.3923/jpt.2006.201.233

    184. Babizhayev, M.A.. Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops. Rejuvenation Research , 7: 186-198 (2004). (PubMed: 15588519)
    doi:10.1089/rej.2004.7.186
    http://dx.doi.org/10.1089/rej.2004.7.186

    185. Babizhayev, M.A., Yermakova, V.N., Deyev, A.I., Seguin, M.-C. . Imidazole-containing peptidomimetic NACA as a potent drug for the medicinal treatment of age-related cataract in humans. J. Anti-Aging Medicine , 3: 43-62 (2000).

    186. Babizhayev, M. A., Yermakova, V. N., Sakina, N. L., Evstigneeva, R.P., Rozhkova, E.A., Zheltukhina,G.A. Nα-Acetylcarnosine is a prodrug of L-carnosine in ophthalmic application as antioxidant. Clin. Chim. Acta , 254, 1-21 (1996). (PubMed: 8894306)
    doi:10.1016/0009-8981%2896%2906356-5
    http://dx.doi.org/10.1016/0009-8981%2896%2906356-5

    187.Babizhayev MA, Bozzo Costa E. Composizioni farmaceutiche contenenti N-acetilcarnosina per il trattamento della cataratta. Italian Patent A61K gruppo 37/00 20122 MI, Priority Oct. 15, 1993.

    188. Babizhayev MA, Bozzo Costa E. Pharmaceutical compositions containing N-acetylcarnosine for the treatment of cataract. Patent PCT/EP 94/03340 SCB 238 PCT, Oct. 10, 1994.

    189. Babizhayev MA. Ocular drug metabolism of the bioactivating antioxidant N-acetylcarnosine for vision in ophthalmic prodrug and codrug design and delivery. Drug Dev Ind Pharm. , Oct;34 (10):1071-89 (2008). (PubMed: 18777243)
    doi:10.1080/03639040801958413
    http://dx.doi.org/10.1080/03639040801958413

    190. Rekker RF. The hydrophobic fragmental constant (1977). Amsterdam.

    191. O'Dowd JJ, Robins DJ, Miller DJ. Detection, characterisation, and quantification of carnosine and other histidyl derivatives in cardiac and skeletal muscle. Biochim Biophys Acta. , Nov 17;967 (2):241-9 (1988). (PubMed: 3263885 )
    doi:10.1016/0304-4165(88)90015-3
    http://dx.doi.org/10.1016/0304-4165(88)90015-3

    192. Babizhayev, M.A., Yermakova, V.N., Semiletov, Yu.A., Deyev, A.I. .The natural histidine-containing dipeptide N-acetylcarnosine as an antioxidant for ophthalmic use. Biochemistry (Moscow) , 65, 588- 598 (2000). (PubMed: 10851037)

    193. Hepsen IF, Yildirim Z, Yilmaz H, Kotuk M. Preventive effect of lacrimal occlusion on topical timolol-induced bronchoconstriction in asthmatics. Clin Experiment Ophthalmol. , Dec;32 (6):597-602 (2004). (PubMed: 15575830 )
    doi:10.1111/j.1442-9071.2004.00909.x
    http://dx.doi.org/10.1111/j.1442-9071.2004.00909.x

    194. Otani H, Okumura A, Nagai K, Okumura N. Colocalization of a carnosine-splitting enzyme, tissue carnosinase (CN2)/cytosolic non-specific dipeptidase 2 (CNDP2), with histidine decarboxylase in the tuberomammillary nucleus of the hypothalamus. Neurosci Lett. 445 (2):166-9 (2008) Sep 7. (Epub ahead of print). (PubMed: 18790006)
    doi:10.1016/j.neulet.2008.09.008
    http://dx.doi.org/10.1016/j.neulet.2008.09.008

    195. Daniel J. Uhlrich, Karen A. Manning, and Jin-Tang Xue. Effects of Activation of the Histaminergic Tuberomammillary Nucleus on Visual Responses of Neurons in the Dorsal Lateral Geniculate Nucleus. J Neuroscience , 22 (3):1098-1107 (2002). (PubMed: 11826138)

    196. Babizhayev M. Failure to withstand oxidative stress induced by phospholipid hydroperoxides as a possible cause of the lens opacities in systemic diseases and ageing. Biochim Biophys Acta. , 1315 (2):87-99 (1996). (PubMed: 8608175)
    doi:10.1016/0925-4439%2895%2900091-7
    http://dx.doi.org/10.1016/0925-4439%2895%2900091-7

    197. Holliday R, McFarland GA. A role for carnosine in cellular maintenance. Biochemistry (Mosc). , Jul;65 (7):843-8 (2000). (PubMed: 10951103)

    198. McFarland GA, Holliday R. Retardation of the senescence of cultured human diploid fibroblasts by carnosine. Exp Cell Res. , Jun;212 (2):167-75 (1994). (PubMed: 8187813)
    doi:10.1006/excr.1994.1132
    http://dx.doi.org/10.1006/excr.1994.1132

    199. McFarland GA, Holliday R. Further evidence for the rejuvenating effects of the dipeptide L-carnosine on cultured human diploid fibroblasts. Exp Gerontol. , Jan;34 (1):35-45 (1999). (PubMed: 10197726)
    doi:10.1016/S0531-5565%2898%2900056-4
    http://dx.doi.org/10.1016/S0531-5565%2898%2900056-4

    200. Shao L, Li QH, Tan Z. L-carnosine reduces telomere damage and shortening rate in cultured normal fibroblasts. Biochem Biophys Res Commun. , Nov 12;324 (2):931-6 (2004). (PubMed: 15474517)
    doi:10.1016/j.bbrc.2004.09.136
    http://dx.doi.org/10.1016/j.bbrc.2004.09.136

    201. Boldyrev AA, Gallant SC, Sukhich GT. Carnosine, the protective, anti-aging peptide. Biosci Rep. 1999 Dec;19 (6):581-7 (1999). (PubMed: 10841274)
    doi:10.1023/A%3A1020271013277
    http://dx.doi.org/10.1023/A%3A1020271013277

    202. Olovnikov AM. Hypothesis: lifespan is regulated by chronomere DNA of the hypothalamus. J Alzheimers Dis. , May;11 (2):241-52 (2007). (PubMed: 17522448 )

    203. Nishi O, Nishi K, Fujiwara T, Shirasawa E. Types of collagen synthesised by the lens epithelial cells of human cataracts. Br J Ophthalmol October; 79 (10): 939-943 (1995). (PubMed: 7488584)
    doi:10.1136/bjo.79.10.939
    http://dx.doi.org/10.1136/bjo.79.10.939

    Abbreviations: VEGF: vascular endothelial growth factor; FGF: fibroblast growth factor; ESAF:endothelial cell-stimulating, angiogenic growth factor; Ang: angiopoietin; TGF: transforming growth factor; PDGF: platelet derived growth factor; Ach: acetylcholine; NO: nitric oxide; NP: nitroprusside

    Key Words: Telomere Shortening, Telomerase, Human Lens Cells, Aging And Cataract, Lifespan, Telomere-Dependent Senescent Phenotype, Biological Marker, Carnosine, N-Acetylcarnosine Ophthalmic Prodrug, Cataract Treatment, Basic Preventive Health Care, After-Cataract Prevention, Review

    Send correspondence to: Mark A. Babizhayev, Innovative Vision Products, Inc., Moscow Division, Ivanovskaya 20, Suite 74 Moscow 127434 Russian Federation, Tel/Fax: 7-495-977-2387, Fax: 7-495-977-2387, E-mail:markbabizhayev@mail.ru